



# 中山醫學大學附設醫院

## 泌尿道系統癌診療指引

2025/12/19 Version18.0  
2024/11/22 Version17.0  
2023/11/17 Version16.0  
2023/06/09 Version15.0  
2022/12/09Version14.0  
2021/12/17Version 13.0  
2020/11/27 Version 12.0  
2019/12/06 Version 11.0  
2018/04/02 Version 10.0  
2017/12/01 Version 9.0  
2016/11/04 Version 8.0  
2015/11/20 Version 7.0  
2014/12/19 Version 6.0  
2013/12/27 Version 5.0  
2012/12/07 Version 4.0  
2011/11/18 Version 3.1  
2011/01/21 Version 3.0  
2010/05/28 Version 2.0  
2009/12/16 Version 1.0

臨床指引參考台灣國家衛生研究院、與美國 NCCN 版本

再依據中山醫學大學附設醫院泌尿道癌小組經驗作編修

112.4 月癌委會提案通過除膀胱癌，新增腎癌、腎盂癌、輸尿管癌為泌尿道系統癌

癌症委員會主任委員	癌症委員會執行長	癌症中心主任	抗癌藥物安全小組	團隊負責人
詹光川	蔡明志	謝政	吳敬煒	陳子棠



修訂內容

頁數	第 17 版	第 18 版																																		
第 1 頁	美國 National Comprehensive Cancer Network (NCCN) 的 Practice Guide-lines in Bladder Cancer-V5 2024 版	美國 National Comprehensive Cancer Network (NCCN) 的 Practice Guide-lines in Bladder Cancer-Version 2 2025 版																																		
第 5 頁	WORK-UP	新增 主要項目 選擇性項目																																		
第 9 頁	If patient prefers bladder preservation or is unable to undergo cystectomy, ● concurrent chemoradiotherapy. ● R/T ● TURBT	刪除 TURBT																																		
第 10 頁	If patient prefers bladder preservation or is unable to undergo cystectomy, ● concurrent chemoradiotherapy. ● R/T ● TURBT	刪除 TURBT																																		
第 27 頁	無	新增 or Stereotactic body radiation therapy (SBRT)																																		
第 33 頁	<p>五、化學及放射線治療<sup>42</sup></p> <p>5-1 泌尿道上皮癌(含腎盂癌、輸尿管癌、膀胱癌)<sup>42</sup></p> <p><b>Principles of SYSTEMIC THERAPY<sup>42</sup></b></p> <p><b>Intravesical chemotherapy for Tis, Ta 及 T1 cancer<sup>42</sup></b></p> <p>Gemcitabine 每次灌洗 2000mg，連續三周每周兩次<sup>42</sup></p> <p>Mitomycin (Mitomycin-C) 30mg qw x6 and /or qm x3<sup>42</sup></p> <p>Phamtarubicin 30mg qw x6 and/or qm x3<sup>42</sup></p> <p>BCG 120mg qw x6 and/or qm x3<sup>42</sup></p> <p><sup>42</sup></p> <table border="1"> <tr> <td>Neoadjuvant chemotherapy [preferred for bladder]<sup>42</sup></td> <td></td> </tr> <tr> <td>Preferred regimen<sup>42</sup></td> <td></td> </tr> <tr> <td>• DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin) with growth factor support for 3-6 cycles<sup>42</sup></td> <td></td> </tr> <tr> <td>Other recommended regimens<sup>42</sup></td> <td></td> </tr> <tr> <td>• Gemcitabine and cisplatin for 4 cycles<sup>42</sup></td> <td></td> </tr> </table> <p><sup>42</sup></p> <table border="1"> <tr> <td>Adjuvant therapy<sup>42</sup></td> <td></td> </tr> <tr> <td>No previous platinum-based neoadjuvant therapy (pT3, pT4a, pN+)<sup>42</sup></td> <td>Preferred regimen<sup>42</sup></td> </tr> <tr> <td></td> <td>• DDMVAC with growth factor support for 3-6 cycles<sup>42</sup></td> </tr> <tr> <td></td> <td>Other recommended regimens<sup>42</sup></td> </tr> </table> <p><sup>42</sup></p>	Neoadjuvant chemotherapy [preferred for bladder] <sup>42</sup>		Preferred regimen <sup>42</sup>		• DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin) with growth factor support for 3-6 cycles <sup>42</sup>		Other recommended regimens <sup>42</sup>		• Gemcitabine and cisplatin for 4 cycles <sup>42</sup>		Adjuvant therapy <sup>42</sup>		No previous platinum-based neoadjuvant therapy (pT3, pT4a, pN+) <sup>42</sup>	Preferred regimen <sup>42</sup>		• DDMVAC with growth factor support for 3-6 cycles <sup>42</sup>		Other recommended regimens <sup>42</sup>	<p>五、化學及放射線治療<sup>42</sup></p> <p>5-1 泌尿道上皮癌(含腎盂癌、輸尿管癌、膀胱癌)<sup>42</sup></p> <p><b>Principles of SYSTEMIC THERAPY<sup>42</sup></b></p> <p><b>▲ Intravesical chemotherapy for Tis, Ta 及 T1 cancer<sup>42</sup></b></p> <p>Gemcitabine 每次灌洗 2000mg，連續三周每周兩次<sup>42</sup></p> <p>Mitomycin (Mitomycin-C) 30mg qw x6 and /or qm x3<sup>42</sup></p> <p>Phamtarubicin 30mg qw x6 and/or qm x3<sup>42</sup></p> <p>BCG 120mg qw x6 and/or qm x3<sup>42</sup></p> <p><sup>42</sup></p> <table border="1"> <tr> <td>Neoadjuvant chemotherapy [preferred for bladder]<sup>42</sup></td> <td>Perioperative/Sandwich Therapy<sup>42</sup></td> </tr> <tr> <td>Preferred regimen<sup>42</sup></td> <td>Preferred regimen<sup>42</sup></td> </tr> <tr> <td>• DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin) with growth factor support for 3-6 cycles<sup>42</sup></td> <td>• Gemcitabine + cisplatin + durvalumab prior to cystectomy, then durvalumab after cystectomy<sup>5</sup> (for bladder cancer only) (category 1)<sup>42</sup></td> </tr> <tr> <td>Other recommended regimens<sup>42</sup></td> <td></td> </tr> <tr> <td>• Gemcitabine and cisplatin for 4 cycles<sup>42</sup></td> <td></td> </tr> </table> <p><sup>42</sup></p> <table border="1"> <tr> <td>Adjuvant therapy<sup>42</sup></td> <td></td> </tr> <tr> <td>No previous platinum-based neoadjuvant therapy (pT3, pT4a, pN+)<sup>42</sup></td> <td>Preferred regimen<sup>42</sup></td> </tr> <tr> <td></td> <td></td> </tr> </table> <p><sup>42</sup></p>	Neoadjuvant chemotherapy [preferred for bladder] <sup>42</sup>	Perioperative/Sandwich Therapy <sup>42</sup>	Preferred regimen <sup>42</sup>	Preferred regimen <sup>42</sup>	• DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin) with growth factor support for 3-6 cycles <sup>42</sup>	• Gemcitabine + cisplatin + durvalumab prior to cystectomy, then durvalumab after cystectomy <sup>5</sup> (for bladder cancer only) (category 1) <sup>42</sup>	Other recommended regimens <sup>42</sup>		• Gemcitabine and cisplatin for 4 cycles <sup>42</sup>		Adjuvant therapy <sup>42</sup>		No previous platinum-based neoadjuvant therapy (pT3, pT4a, pN+) <sup>42</sup>	Preferred regimen <sup>42</sup>		
Neoadjuvant chemotherapy [preferred for bladder] <sup>42</sup>																																				
Preferred regimen <sup>42</sup>																																				
• DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin) with growth factor support for 3-6 cycles <sup>42</sup>																																				
Other recommended regimens <sup>42</sup>																																				
• Gemcitabine and cisplatin for 4 cycles <sup>42</sup>																																				
Adjuvant therapy <sup>42</sup>																																				
No previous platinum-based neoadjuvant therapy (pT3, pT4a, pN+) <sup>42</sup>	Preferred regimen <sup>42</sup>																																			
	• DDMVAC with growth factor support for 3-6 cycles <sup>42</sup>																																			
	Other recommended regimens <sup>42</sup>																																			
Neoadjuvant chemotherapy [preferred for bladder] <sup>42</sup>	Perioperative/Sandwich Therapy <sup>42</sup>																																			
Preferred regimen <sup>42</sup>	Preferred regimen <sup>42</sup>																																			
• DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin) with growth factor support for 3-6 cycles <sup>42</sup>	• Gemcitabine + cisplatin + durvalumab prior to cystectomy, then durvalumab after cystectomy <sup>5</sup> (for bladder cancer only) (category 1) <sup>42</sup>																																			
Other recommended regimens <sup>42</sup>																																				
• Gemcitabine and cisplatin for 4 cycles <sup>42</sup>																																				
Adjuvant therapy <sup>42</sup>																																				
No previous platinum-based neoadjuvant therapy (pT3, pT4a, pN+) <sup>42</sup>	Preferred regimen <sup>42</sup>																																			



Von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol* 2000; 18:3068-<sup>62</sup>

<b>CMV<sup>62</sup></b>			
Cisplatin	70 mg/m <sup>2</sup> iv		d2 <sup>62</sup>
Vinblastine	4 mg/m <sup>2</sup> iv		d1, 8 <sup>62</sup>
Methotrexate	30 mg/m <sup>2</sup> iv		d1, 8 <sup>62</sup>

Q3w x 3 cycles<sup>62</sup>

International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle invasive bladder cancer: a randomized controlled trial. *Lancet* 1999; 354:533<sup>64</sup>

**Concurrent chemoradiation for stage II, III and non-metastatic stage IV cancer<sup>63</sup>**

<b>Cisplatin<sup>63</sup></b>			
Cisplatin	30-40 mg/m <sup>2</sup> iv	or	Carboplatin AUC 2
			d1 <sup>63</sup>

Q1w x 6 cycles<sup>63</sup>

Tanaka MA et al. Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation (SIUT). *J Pak Med Assoc* 2011; 61:6. <sup>64</sup>

**Chemotherapy for metastatic cancer<sup>64</sup>**

**Principles of systemic therapy<sup>64</sup>**

**First-line chemotherapy for locally advanced or metastatic disease(Stage IV)<sup>64</sup>**

Cisplatin eligible <sup>64</sup>	<b>Preferred regimens<sup>64</sup></b>
	• Pembrolizumab and <b>enfortumab vedotin-ejfv</b> (category 1) <sup>64</sup>
Cisplatin ineligible <sup>64</sup>	<b>Other recommended regimens<sup>64</sup></b>
	• Gemcitabine and cisplatin (category 1) followed by avelumab maintenance therapy (category 1) <sup>64</sup>
	• Nivolumab, gemcitabine, and cisplatin (category 1) followed by nivolumab maintenance therapy(category 1) <sup>64</sup>
	<b>Useful under certain circumstances<sup>64</sup></b>
	• DDMVAC with growth factor support (category 1) followed by avelumab maintenance therapy (category 1) <sup>64</sup>

Cisplatin ineligible <sup>64</sup>	<b>Preferred regimens<sup>64</sup></b>
	• Gemcitabine and carboplatin followed by avelumab maintenance therapy <sup>64</sup>
	• Pembrolizumab (for the treatment of patients with locally advanced or metastatic urothelial carcinoma <b>who are</b>

<b>CMV<sup>62</sup></b>			
Cisplatin	70 mg/m <sup>2</sup> iv		d2 <sup>62</sup>
Vinblastine	4 mg/m <sup>2</sup> iv		d1, 8 <sup>62</sup>
Methotrexate	30 mg/m <sup>2</sup> iv		d1, 8 <sup>62</sup>

Q3w x 3 cycles<sup>62</sup>

International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle invasive bladder cancer: a randomized controlled trial. *Lancet* 1999; 354:533<sup>64</sup>

**Neoadjuvant Chemotherapy with Immunotherapy<sup>64</sup>**

Gemcitabine	1000-1250 mg/m <sup>2</sup> iv		d1, 8
Cisplatin	100 mg/m <sup>2</sup> iv		d1 <sup>64</sup>
Durvalumab	1500 mg		d1 <sup>64</sup>

Q3w x 4 cycles <sup>64</sup>

**Peri-operative use of Durvalumab<sup>63</sup>**

Thomas Powles, M.D., James W.F. Catto, Ph.D., F.R.C.S.(Urol), **Toan Quang Vu, M.D.**, for the NIAGARA Investigators; Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. *N Engl J Med* 2024;391:1773-1786 VOL. 391 NO. 19<sup>64</sup>

<b>Enfortumab Vedotin</b>	1.25 mg/Kg		d1, 8
<b>Pembrolizumab</b>	200 mg		d1 <sup>64</sup>

Q3w x 3 cycles<sup>63</sup>

1. Cis-ineligible 2. Peri-operative use of EV+P<sup>63</sup>

<b>Enfortumab Vedotin</b>	1.25 mg/Kg		d1, 8
<b>Pembrolizumab</b>	200 mg		d1 <sup>64</sup>

Q3w x 4 cycles<sup>63</sup>

1. Cis-eligible 2. Peri-operative use of EV+P<sup>63</sup>

無

Chung Shan Medical University Hospital 泌尿道系統癌治療指引 Clinical Guideline 2026 version18.0

**Adjuvant regimens<sup>64</sup>**

**CheckMate 274<sup>64</sup>**

Nivolumab	240 mg		q2w <sup>64</sup>
-----------	--------	--	-------------------

1 year<sup>64</sup>

Dean F. **Bajorin**, M.D., J. Alfred **Witjes**, M.D., Matthew D. **Galsky**, M.D. Published June 2, 2021. *N Engl J Med* 2021;384:2102-2114. DOI: 10.1056/NEJMoa2034442. VOL. 384 NO. 22<sup>64</sup>

**MVAC<sup>64</sup>**

Methotrexate	30 mg/m <sup>2</sup> iv		d1, 15 and 22 <sup>64</sup>
Vinblastine	3 mg/m <sup>2</sup> iv		d2, 15 and 22 <sup>64</sup>
Doxorubicin	30 mg/m <sup>2</sup> iv		d2 <sup>64</sup>
Cisplatin	70 mg/m <sup>2</sup> iv		d1 <sup>64</sup>
Carboplatin	AUC 4-6		d1 <sup>64</sup>
Avelumab	10mg/Kg		q2w

Q4w x 6 cycles<sup>64</sup>

Useful under certain circumstances<sup>64</sup>

Sternberg CN, de Mulder PH, **Schornagel** JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. *J Clin Oncol* 2001;19:2638-2646.<sup>64</sup>

**EV 301 trial<sup>64</sup>**

<b>Enfortumab vedotin-ejfv</b>	1.25 mg/kg		d1, 8, 15 <sup>64</sup>
--------------------------------	------------	--	-------------------------

q4w<sup>64</sup>

Thomas Powles, M.D., Jonathan E. Rosenberg, M.D., Daniel P. Petrylak, M.D. Author Info & Affiliations. Published February 12, 2021. *N Engl J Med* 2021;384:1125-1135. DOI: 10.1056/NEJMoa2035807. VOL. 384 NO. 12.<sup>64</sup>

**Gemcitabine+ Carboplatin<sup>64</sup>**

Gemcitabine	800 - 1000 mg/m <sup>2</sup> iv		d1, 8 and 15 <sup>64</sup>
Carboplatin	AUC 4-6		d1 <sup>64</sup>

Q4w x 3 cycles<sup>64</sup>

Von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol* 2000; 18:3068<sup>62</sup>

**Gemcitabine+ Cisplatin<sup>64</sup>**

Gemcitabine	800 - 1000 mg/m <sup>2</sup> iv		d1, 8 and 15 <sup>64</sup>
Cisplatin	70 mg/m <sup>2</sup> iv d2		d1 <sup>64</sup>

Q4w x 3 cycles<sup>64</sup>

Von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol* 2000; 18:3068<sup>62</sup>



<p><b>Second-line systemic therapy for locally advanced or metastatic disease (Stage IV) (post-platinum)<sup>e1</sup></b>  <b>Participation in clinical trials of new agents is recommended.<sup>e2</sup></b></p>	
<p>Preferred regimen<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Pembrolizumab (category 1 post-platinum)<sup>e2</sup></li> </ul>	<p>Other recommended regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Paclitaxel or docetaxel<sup>e1</sup></li> <li>• Gemcitabine<sup>e1</sup></li> <li>• Pembrolizumab and <b>enfortumab vedotin-ejfv</b> (category 2B)<sup>e2</sup></li> </ul>
<p>Alternative preferred regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Nivolumab<sup>e1</sup></li> <li>• Avelumab<sup>e1</sup></li> <li>• Erdafitinib<sup>e1</sup></li> <li>• <b>Enfortumab vedotin-ejfv</b><sup>e2</sup></li> </ul>	<p>Useful in certain circumstances based on prior medical therapy<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Ifosfamide, doxorubicin, and gemcitabine<sup>e1</sup></li> <li>• Gemcitabine and paclitaxel<sup>e1</sup></li> <li>• Gemcitabine and cisplatin<sup>e1</sup></li> <li>• DDMVAC with growth factor support<sup>e2</sup></li> </ul>
<p><b>Second-line systemic therapy for locally advanced or metastatic disease (Stage IV) (post-checkpoint inhibitor)<sup>e1</sup></b>  <b>Participation in clinical trials of new agents is recommended.<sup>e2</sup></b></p>	
<p>Preferred regimen for cisplatin <del>ineligible chemotherapy</del> naïve<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• <b>Enfortumab vedotin-ejfv</b><sup>e2</sup></li> <li>• Gemcitabine/carboplatin<sup>e1</sup></li> <li>• Erdafitinib<sup>e1</sup></li> </ul>	<p>Other recommended regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Paclitaxel or docetaxel<sup>e1</sup></li> <li>• Gemcitabine<sup>e1</sup></li> </ul>
<p>Preferred regimens for cisplatin eligible,<sup>e1</sup> chemotherapy naïve<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Gemcitabine and cisplatin<sup>e1</sup></li> </ul>	<p>Useful in certain circumstances based on prior medical therapy<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Ifosfamide, doxorubicin, and gemcitabine<sup>e1</sup></li> <li>• Gemcitabine and paclitaxel<sup>e1</sup></li> </ul>
<ul style="list-style-type: none"> <li>• DDMVAC with growth factor support<sup>e1</sup></li> <li>• Erdafitinib<sup>e1</sup></li> </ul>	
<p><b>Subsequent-Line Systemic Therapy for Locally Advanced or Metastatic Disease (Stage IV)Participation in clinical trials of new agents is recommended.<sup>e2</sup></b></p>	
<p>Preferred regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• <b>Enfortumab vedotin-ejfv</b> (category 1)<sup>e2</sup></li> <li>• Erdafitinib<sup>e1</sup></li> </ul>	<p>Other recommended regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Sacituzumab <b>govitecan-hziv</b><sup>e1</sup></li> <li>• Gemcitabine<sup>e1</sup></li> <li>• Paclitaxel or docetaxel<sup>e1</sup></li> <li>• Ifosfamide, doxorubicin, and gemcitabine<sup>e1</sup></li> <li>• Gemcitabine and paclitaxel<sup>e1</sup></li> <li>• Gemcitabine and cisplatin<sup>e1</sup></li> <li>• DDMVAC with growth factor support<sup>e2</sup></li> </ul>

<p><b>MVAC<sup>e1</sup></b></p>		
Methotrexate	30 mg/m <sup>2</sup> iv	d1, 15 and 22 <sup>e1</sup>
Vinblastine	3 mg/m <sup>2</sup> iv	d2, 15 and 22 <sup>e1</sup>
Doxorubicin	30 mg/m <sup>2</sup> iv	d2 <sup>e1</sup>
Cisplatin	70 mg/m <sup>2</sup> iv or Carboplatin AUC 4-6	d1 or 2 <sup>e1</sup>
<p>Q4w x 6 cycles<sup>e1</sup></p> <p>Han KS et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer 2008; 98:86. <sup>e1</sup></p> <p>Logotheis CJ et al. A prospective randomized trial comparing MVAC with CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8:1050. <sup>e1</sup></p>		
<p><b>Gemcitabine + Cisplatin(Carboplatin)<sup>e1</sup></b></p>		
Gemcitabine	800 - 1000 mg/m <sup>2</sup> iv	d1, 8 and 15 <sup>e1</sup>
Cisplatin	70 mg/m <sup>2</sup> iv	d2 <sup>e1</sup>
<p>Q4w x 6 cycles<sup>e1</sup></p> <p>von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068<sup>e1</sup></p>		

<p><b>Second-Line Systemic Therapy for Locally Advanced or Metastatic Disease (Stage IV)<sup>e2</sup></b>  <b>Previous immunotherapy and enfortumab vedotin-ejfv (no previous chemotherapy)<sup>e2</sup></b></p>		
<p>Preferred regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• DDMVAC with growth factor support<sup>e1</sup></li> <li>• Gemcitabine and cisplatin<sup>e1</sup></li> <li>• Gemcitabine and carboplatin (category 2B)<sup>e2</sup></li> <li>• <b>Enfortumab vedotin-ejfv</b><sup>e2</sup></li> <li>• <b>Enfortumab vedotin-ejfv</b> and pembrolizumab<sup>e2</sup></li> <li>• Biomarker-directed therapy (see biomarker-directed therapy table)<sup>e2</sup></li> </ul>	<p>Other recommended regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Paclitaxel or docetaxel<sup>e1</sup></li> <li>• Gemcitabine<sup>e1</sup></li> </ul>	<p>Useful in certain circumstances<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Gemcitabine, cisplatin, and nivolumab (category 2B)<sup>e1</sup></li> <li>• Ifosfamide, doxorubicin, and gemcitabine30 (category 2B)<sup>e1</sup></li> <li>• Gemcitabine and paclitaxel31 (category 2B)<sup>e1</sup></li> </ul>
<p><b>Previous chemotherapy (no previous immunotherapy or enfortumab vedotin-ejfv)<sup>e2</sup></b></p>		
<p>Preferred regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Pembrolizumab (category 1 post-platinum)<sup>e1</sup></li> <li>• <b>Enfortumab vedotin-ejfv</b> and pembrolizumab<sup>e1</sup></li> <li>• <b>Enfortumab vedotin-ejfv</b><sup>e2</sup></li> <li>• Nivolumab(category 2B)<sup>e1</sup></li> <li>• Avelumab (category 2B)<sup>e1</sup></li> <li>• Biomarker-directed therapy (see biomarker-directed therapy table)<sup>e2</sup></li> </ul>	<p>Other recommended regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Paclitaxel or docetaxel<sup>e1</sup></li> <li>• Gemcitabine<sup>e1</sup></li> </ul>	<p>Useful in certain circumstances<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• DDMVAC with growth factor support2 (category 2B)<sup>e1</sup></li> <li>• Ifosfamide, doxorubicin, and gemcitabine30 (category 2B)<sup>e1</sup></li> <li>• Gemcitabine and paclitaxel31 (category 2B)<sup>e1</sup></li> <li>• Gemcitabine and cisplatin4 (category 2B)<sup>e1</sup></li> </ul>
<p><b>Previous chemotherapy and immunotherapy (no previous enfortumab vedotin-ejfv)<sup>e2</sup></b></p>		
<p>Preferred regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• <b>Enfortumab vedotin-ejfv</b>(category 1)<sup>e2</sup></li> <li>• Biomarker-directed therapy (see biomarker-directed therapy table)<sup>e2</sup></li> </ul>	<p>Other recommended regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• <b>Enfortumab vedotin-ejfv</b> and pembrolizumab<sup>e1</sup></li> <li>• Paclitaxel or docetaxel<sup>e1</sup></li> <li>• Gemcitabine<sup>e1</sup></li> <li>• Gemcitabine and cisplatin4<sup>e1</sup></li> <li>• DDMVAC with growth factor support2<sup>e1</sup></li> </ul>	<p>Useful in certain circumstances<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Sacituzumab <b>govitecan-hziv</b><sup>e2</sup></li> </ul>
<ul style="list-style-type: none"> <li>• Ifosfamide, doxorubicin, and gemcitabine (category 2B)<sup>e1</sup></li> <li>• Gemcitabine and paclitaxel (category 2B)<sup>e2</sup></li> </ul>		
<p><b>Subsequent-Line Systemic Therapy for Locally Advanced or Metastatic Disease (Stage IV)<sup>e2</sup></b>  <b>Previous chemotherapy, immunotherapy, and enfortumab vedotin-ejfv<sup>e2</sup></b></p>		
<p>Preferred regimen<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Biomarker-directed therapy Biomarker-directed therapy (see biomarker-directed therapy table)<sup>e2</sup></li> </ul>	<p>Other recommended regimens<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Gemcitabine<sup>e1</sup></li> <li>• Paclitaxel or docetaxel<sup>e1</sup></li> <li>• Ifosfamide, doxorubicin, and gemcitabine(category 2B)<sup>e1</sup></li> <li>• Gemcitabine and paclitaxel31 (category 2B)<sup>e2</sup></li> </ul>	<p>Useful in certain circumstances<sup>e1</sup></p> <ul style="list-style-type: none"> <li>• Sacituzumab <b>govitecan-hziv</b><sup>e2</sup></li> </ul>

<p><b>Unresectable/metastatic regimens<sup>e1</sup></b></p>		
<p><b>MVAC<sup>e1</sup></b></p>		
Methotrexate	30 mg/m <sup>2</sup> iv	d1, 15 and 22 <sup>e1</sup>
Vinblastine	3 mg/m <sup>2</sup> iv	d2, 15 and 22 <sup>e1</sup>
Doxorubicin	30 mg/m <sup>2</sup> iv	d2 <sup>e1</sup>
Cisplatin	70 mg/m <sup>2</sup> iv	d1 <sup>e1</sup>
Carboplatin	AUC 4	d2 <sup>e1</sup>
<p>Q4w x 3 cycles<sup>e1</sup></p> <p>Grossman HB et al. <b>Neoadjuvant</b> chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Eng J Med 2003; 349:859. <sup>e1</sup></p>		
<p><b>Gemcitabine+ Cisplatin+ Nivolumab<sup>e1</sup></b></p>		
Gemcitabine	800 - 1000 mg/m <sup>2</sup> iv	d1, 8 and 15 <sup>e1</sup>
Cisplatin	70 mg/m <sup>2</sup> iv	d1 <sup>e1</sup>
Nivolumab	100-200mg	d1 <sup>e1</sup>
<p>Q4w x 3 cycles<sup>e1</sup></p> <p>Von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068<sup>e1</sup></p>		



第40頁	無	<p><b>EV 302 trial</b><sup>↵</sup></p> <table border="1"> <tr><td>Enfortumab Vedotin</td><td>1.25 mg/Kg</td><td>d1, 8</td></tr> <tr><td>Pembrolizumab</td><td>200 mg</td><td>d1</td></tr> <tr><td>Q3w x 4 cycles</td><td></td><td></td></tr> <tr><td>35 cycles for Pembrolizumab</td><td></td><td></td></tr> </table> <p>Thomas Powles, M.D., Gopa Iyer, M.D., Published March 6, 2024. <i>N Engl J Med</i> 2024;390:875-888. DOI: 10.1056/NEJMoa2312117. VOL. 390 NO. 10</p> <p><b>JAVELINE 100 trial</b><sup>↵</sup></p> <table border="1"> <tr><td>Avelumab</td><td>10mg/Kg</td><td>q2w</td></tr> <tr><td>Gemcitabine</td><td>1000-1250 mg/m<sup>2</sup> iv</td><td>d1, 8 and 15</td></tr> <tr><td>Cisplatin</td><td>70 mg/m<sup>2</sup> iv</td><td>d1</td></tr> <tr><td>Avelumab as 1st line maintenance</td><td></td><td></td></tr> </table> <p>Thomas Powles, M.D., Se Hoon Park, M.D., Ph.D., Petros Grivas, M.D., Ph.D. Author Info &amp; Affiliations. Published September 18, 2020. <i>N Engl J Med</i> 2020;383:1218-1230. DOI: 10.1056/NEJMoa2002788. VOL. 383 NO. 13</p> <p><b>JAVELINE 100 trial</b><sup>↵</sup></p> <table border="1"> <tr><td>Avelumab</td><td>10mg/Kg</td><td>q2w</td></tr> <tr><td>Gemcitabine</td><td>1000-1250 mg/m<sup>2</sup> iv</td><td>d1, 8</td></tr> <tr><td>Cisplatin</td><td>70 mg/m<sup>2</sup> iv</td><td>d1</td></tr> <tr><td>Avelumab as 1st line maintenance</td><td></td><td></td></tr> </table> <p>Thomas Powles, M.D., Se Hoon Park, M.D., Ph.D., Petros Grivas, M.D., Ph.D. Author Info &amp; Affiliations. Published September 18, 2020. <i>N Engl J Med</i> 2020;383:1218-1230. DOI: 10.1056/NEJMoa2002788. VOL. 383 NO. 13</p> <p><b>Key Note 045 trial</b><sup>↵</sup></p> <table border="1"> <tr><td>Pembrolizumab</td><td>200 mg</td><td>q3w</td></tr> <tr><td>2 years</td><td></td><td></td></tr> </table> <p>Joaquim Bellmunt, M.D., Lawrence Fong, M.D., Nicholas J. Vogelzang, M.D., Published March 16, 2017. <i>N Engl J Med</i> 2017;376:1015-1026. DOI: 10.1056/NEJMoa1613683. VOL. 376 NO. 11</p>	Enfortumab Vedotin	1.25 mg/Kg	d1, 8	Pembrolizumab	200 mg	d1	Q3w x 4 cycles			35 cycles for Pembrolizumab			Avelumab	10mg/Kg	q2w	Gemcitabine	1000-1250 mg/m <sup>2</sup> iv	d1, 8 and 15	Cisplatin	70 mg/m <sup>2</sup> iv	d1	Avelumab as 1st line maintenance			Avelumab	10mg/Kg	q2w	Gemcitabine	1000-1250 mg/m <sup>2</sup> iv	d1, 8	Cisplatin	70 mg/m <sup>2</sup> iv	d1	Avelumab as 1st line maintenance			Pembrolizumab	200 mg	q3w	2 years		
Enfortumab Vedotin	1.25 mg/Kg	d1, 8																																										
Pembrolizumab	200 mg	d1																																										
Q3w x 4 cycles																																												
35 cycles for Pembrolizumab																																												
Avelumab	10mg/Kg	q2w																																										
Gemcitabine	1000-1250 mg/m <sup>2</sup> iv	d1, 8 and 15																																										
Cisplatin	70 mg/m <sup>2</sup> iv	d1																																										
Avelumab as 1st line maintenance																																												
Avelumab	10mg/Kg	q2w																																										
Gemcitabine	1000-1250 mg/m <sup>2</sup> iv	d1, 8																																										
Cisplatin	70 mg/m <sup>2</sup> iv	d1																																										
Avelumab as 1st line maintenance																																												
Pembrolizumab	200 mg	q3w																																										
2 years																																												
第41頁	無	<p><b>TKI</b><sup>↵</sup></p> <table border="1"> <tr><td>藥名(學名)</td><td>Erdafitinib</td></tr> <tr><td>Ref.</td><td>8 mg po daily initially; increase to 9 mg po daily</td></tr> </table> <p><i>Yohann Lortot, M.D., Ph.D., Nobuaki Matsubara, M.D., Se Hoon Park, M.D., Ph.D., Robert A. Huddart, M.B., B.S., Ph.D., Earle F. Burgess, M.D., Banek M.D., Published October 20, 2023. N Engl J Med 2023;389:1961-1971. DOI: 10.1056/NEJMoa2308849. VOL. 389 NO. 21</i></p>	藥名(學名)	Erdafitinib	Ref.	8 mg po daily initially; increase to 9 mg po daily																																						
藥名(學名)	Erdafitinib																																											
Ref.	8 mg po daily initially; increase to 9 mg po daily																																											
第41頁	<p><b>Principles of radiation</b> <sup>↵</sup></p> <p><i>Selective adjuvant radiotherapy</i> #<sup>↵</sup></p> <p>If margin positive/residual or LN positive, dose of 50~70Gy depends on the tumor position and the patient condition</p> <p><i>Definitive radiotherapy</i> * <sup>↵</sup></p> <p>60~70Gy, depended on the tumor position and the patient status. <sup>↵</sup></p> <p><b>Palliative radiotherapy</b> ** <sup>↵</sup></p> <p>20~40Gy, depended on the disease condition and the patient status.</p> <p>←</p> <p>Temsirolimu</p> <p>Tivozanib</p>	<p><b>Principles of radiation (Bladder Cancer)</b><sup>↵</sup></p> <table border="1"> <thead> <tr> <th>Indication</th> <th>Target Volume</th> <th>建議劑量與分割 Dose &amp; Fractionation</th> <th>備註 Comments</th> </tr> </thead> <tbody> <tr> <td>Conventional fractionation</td> <td>Whole bladder ± pelvic nodes</td> <td>1.8–2.0 Gy / fraction</td> <td>每日照射</td> </tr> <tr> <td>Hypofractionation (definitive)</td> <td>Whole bladder</td> <td>55 Gy / 20 fractions</td> <td>Non-inferior to 64 Gy/32 fx</td> </tr> <tr> <td>Definitive RT (initial)</td> <td>Whole bladder</td> <td>39.6–50.4 Gy</td> <td>需後續 boost</td> </tr> <tr> <td>Definitive RT (boost)</td> <td>Whole or partial bladder</td> <td>Total 60–66 Gy</td> <td>依腫瘤位置調整</td> </tr> <tr> <td>Positive margin / ENE</td> <td>Tumor bed / involved nodes</td> <td>54–60 Gy</td> <td>高風險區域</td> </tr> <tr> <td>Adjuvant RT</td> <td>Pelvic nodes (post-RC)</td> <td>45–50.4 Gy</td> <td>pT3–4, pN0–2</td> </tr> <tr> <td>Adjuvant RT (boost)</td> <td>Positive margin / ENE</td> <td>Boost to 54–60 Gy</td> <td>術後高風險</td> </tr> <tr> <td>Palliative RT</td> <td>Symptomatic lesion</td> <td>30 Gy / 10 fx 或 21 Gy / 3 fx</td> <td>止血、止痛</td> </tr> </tbody> </table>	Indication	Target Volume	建議劑量與分割 Dose & Fractionation	備註 Comments	Conventional fractionation	Whole bladder ± pelvic nodes	1.8–2.0 Gy / fraction	每日照射	Hypofractionation (definitive)	Whole bladder	55 Gy / 20 fractions	Non-inferior to 64 Gy/32 fx	Definitive RT (initial)	Whole bladder	39.6–50.4 Gy	需後續 boost	Definitive RT (boost)	Whole or partial bladder	Total 60–66 Gy	依腫瘤位置調整	Positive margin / ENE	Tumor bed / involved nodes	54–60 Gy	高風險區域	Adjuvant RT	Pelvic nodes (post-RC)	45–50.4 Gy	pT3–4, pN0–2	Adjuvant RT (boost)	Positive margin / ENE	Boost to 54–60 Gy	術後高風險	Palliative RT	Symptomatic lesion	30 Gy / 10 fx 或 21 Gy / 3 fx	止血、止痛						
Indication	Target Volume	建議劑量與分割 Dose & Fractionation	備註 Comments																																									
Conventional fractionation	Whole bladder ± pelvic nodes	1.8–2.0 Gy / fraction	每日照射																																									
Hypofractionation (definitive)	Whole bladder	55 Gy / 20 fractions	Non-inferior to 64 Gy/32 fx																																									
Definitive RT (initial)	Whole bladder	39.6–50.4 Gy	需後續 boost																																									
Definitive RT (boost)	Whole or partial bladder	Total 60–66 Gy	依腫瘤位置調整																																									
Positive margin / ENE	Tumor bed / involved nodes	54–60 Gy	高風險區域																																									
Adjuvant RT	Pelvic nodes (post-RC)	45–50.4 Gy	pT3–4, pN0–2																																									
Adjuvant RT (boost)	Positive margin / ENE	Boost to 54–60 Gy	術後高風險																																									
Palliative RT	Symptomatic lesion	30 Gy / 10 fx 或 21 Gy / 3 fx	止血、止痛																																									



		<p style="text-align: center;">刪除 Temsirolimu Tivozanib 新增 Lenvatinib</p>																							
第43頁	無	<p><b>unresectable/metastatic regimens</b><sup>c,d</sup></p> <p><b>CheckMate 9ER</b><sup>c,d</sup></p> <table border="1" data-bbox="1254 438 2094 494"> <tr> <td>Cabozantinib</td> <td>40mg</td> <td>qd<sup>c,d</sup></td> </tr> <tr> <td>Nivolumab</td> <td>240mg</td> <td>q2w<sup>c,d</sup></td> </tr> </table> <p>Q4w x 6 cycles<sup>c,d</sup></p> <p>Choueiri TK, et al. <i>N Engl J Med</i>. 2021;384(9):829-841.<sup>c,d</sup></p> <p><b>CLEAR trial</b><sup>c,d</sup></p> <table border="1" data-bbox="1254 542 2094 598"> <tr> <td>Lenvatinib</td> <td>20mg</td> <td>qd<sup>c,d</sup></td> </tr> <tr> <td>pembrolizumab</td> <td>200 mg</td> <td>q3w<sup>c,d</sup></td> </tr> </table> <p>Q4w x 6 cycles<sup>c,d</sup></p> <p>J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16.<sup>c,d</sup></p>	Cabozantinib	40mg	qd <sup>c,d</sup>	Nivolumab	240mg	q2w <sup>c,d</sup>	Lenvatinib	20mg	qd <sup>c,d</sup>	pembrolizumab	200 mg	q3w <sup>c,d</sup>											
Cabozantinib	40mg	qd <sup>c,d</sup>																							
Nivolumab	240mg	q2w <sup>c,d</sup>																							
Lenvatinib	20mg	qd <sup>c,d</sup>																							
pembrolizumab	200 mg	q3w <sup>c,d</sup>																							
第44頁	無	<p><b>CheckMate 214 trial</b><sup>c,d</sup></p> <table border="1" data-bbox="1355 646 1993 686"> <tr> <td>Ipilimumab</td> <td>1 mg/Kg</td> <td>q3w<sup>c,d</sup></td> </tr> <tr> <td>Nivolumab</td> <td>3 mg/Kg</td> <td>q3w<sup>c,d</sup></td> </tr> </table> <p>4 cycles then NIVO 3mg/Kg q2w<sup>c,d</sup></p> <p>Robert J. Motzer, M.D., Nizar M. Tannir, Elizabeth R. Plimack, M.D., Published March 21, 2018. <i>N Engl J Med</i> 2018;378:1277-1290<sup>c,d</sup></p> <p>DOI: 10.1056/NEJMoa1712126. VOL. 378 NO. 14<sup>c,d</sup></p> <p><b>KeyNote 426</b><sup>c,d</sup></p> <table border="1" data-bbox="1355 734 1993 774"> <tr> <td>Pembrolizumab</td> <td>200 mg</td> <td>q3w<sup>c,d</sup></td> </tr> <tr> <td>Axitinib</td> <td>5mg</td> <td>bid<sup>c,d</sup></td> </tr> </table> <p>35 cycles for Pembrolizumab<sup>c,d</sup></p> <p>Brian I. Rini, M.D., Elizabeth R. Plimack, M.D., Frédéric Pouliot, M.D., Ph.D., Published February 16, 2019. <i>N Engl J Med</i> 2019;380:1116-1127.DOI: 10.1056/NEJMoa1816714. VOL. 380 NO. 12<sup>c,d</sup></p> <p><b>KeyNote 045 trial</b><sup>c,d</sup></p> <table border="1" data-bbox="1355 829 1993 869"> <tr> <td>Pembrolizumab</td> <td>200 mg</td> <td>q3w<sup>c,d</sup></td> </tr> </table> <p>2 years<sup>c,d</sup></p> <p><b>TKI</b><sup>c,d</sup></p> <table border="1" data-bbox="1355 893 2004 949"> <tr> <td>藥名(學名)<sup>c,d</sup></td> <td>Cabozantinib 40-60 mg po qd<sup>c,d</sup></td> </tr> <tr> <td>Ref.<sup>c,d</sup></td> <td>Touk, Choueiri, M.D., Bernard Escudier, M.D., Thomas Powles, M.D., Hans Hammers, M.D., Published November 5, 2015. <i>N Engl J Med</i> 2015;373:1814-1823<sup>c,d</sup></td> </tr> </table> <table border="1" data-bbox="1355 965 2004 1029"> <tr> <td>藥名(學名)<sup>c,d</sup></td> <td>Pazopanib 800mg po qd<sup>c,d</sup></td> </tr> <tr> <td>Ref.<sup>c,d</sup></td> <td>Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. <i>J Clin Oncol</i> 2010; 28: 1061-8<sup>c,d</sup></td> </tr> </table>	Ipilimumab	1 mg/Kg	q3w <sup>c,d</sup>	Nivolumab	3 mg/Kg	q3w <sup>c,d</sup>	Pembrolizumab	200 mg	q3w <sup>c,d</sup>	Axitinib	5mg	bid <sup>c,d</sup>	Pembrolizumab	200 mg	q3w <sup>c,d</sup>	藥名(學名) <sup>c,d</sup>	Cabozantinib 40-60 mg po qd <sup>c,d</sup>	Ref. <sup>c,d</sup>	Touk, Choueiri, M.D., Bernard Escudier, M.D., Thomas Powles, M.D., Hans Hammers, M.D., Published November 5, 2015. <i>N Engl J Med</i> 2015;373:1814-1823 <sup>c,d</sup>	藥名(學名) <sup>c,d</sup>	Pazopanib 800mg po qd <sup>c,d</sup>	Ref. <sup>c,d</sup>	Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. <i>J Clin Oncol</i> 2010; 28: 1061-8 <sup>c,d</sup>
Ipilimumab	1 mg/Kg	q3w <sup>c,d</sup>																							
Nivolumab	3 mg/Kg	q3w <sup>c,d</sup>																							
Pembrolizumab	200 mg	q3w <sup>c,d</sup>																							
Axitinib	5mg	bid <sup>c,d</sup>																							
Pembrolizumab	200 mg	q3w <sup>c,d</sup>																							
藥名(學名) <sup>c,d</sup>	Cabozantinib 40-60 mg po qd <sup>c,d</sup>																								
Ref. <sup>c,d</sup>	Touk, Choueiri, M.D., Bernard Escudier, M.D., Thomas Powles, M.D., Hans Hammers, M.D., Published November 5, 2015. <i>N Engl J Med</i> 2015;373:1814-1823 <sup>c,d</sup>																								
藥名(學名) <sup>c,d</sup>	Pazopanib 800mg po qd <sup>c,d</sup>																								
Ref. <sup>c,d</sup>	Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. <i>J Clin Oncol</i> 2010; 28: 1061-8 <sup>c,d</sup>																								



第 44 頁	無	<table border="1"> <tr> <td>藥名(學名)<sup>23</sup></td> <td>Sunitinib 50 mg po 4/2 or 2/1 week (on/off)<sup>23</sup></td> </tr> <tr> <td>Ref.<sup>23</sup></td> <td>Robert J. Motzer, M.D., Thomas E. Hutson, D.O., Stéphane Oudard, M.D., Published January 11, 2007. <i>N Engl J Med</i> 2007;356:115-124. DOI: 10.1056/NEJMoa065044. VOL. 356 NO. 2<sup>23</sup></td> </tr> <tr> <td>藥名<sup>24</sup></td> <td>Axitinib 5mg po bid<sup>24</sup></td> </tr> <tr> <td>Ref.<sup>24</sup></td> <td><i>The Lancet</i>. Volume 378, Issue 9807p1931-1939December 03, 2011. AXIS trial<sup>24</sup></td> </tr> <tr> <td>藥名<sup>25</sup></td> <td>Everolimus 10mg po qd<sup>25</sup></td> </tr> <tr> <td>Ref.<sup>25</sup></td> <td><i>Ann Oncol</i>. 2016 Mar;27(3):441-8. doi: 10.1093/annonc/mdv612. Epub 2015 Dec 17.<sup>25</sup></td> </tr> <tr> <td>藥名<sup>26</sup></td> <td>Tivozanib 1.34 mg po day1-21<sup>26</sup></td> </tr> <tr> <td>Ref.<sup>26</sup></td> <td>Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TivNivo-2 Study<sup>26</sup></td> </tr> <tr> <td>藥名<sup>27</sup></td> <td>Belzutifan 120 mg po qd<sup>27</sup></td> </tr> <tr> <td>Ref.<sup>27</sup></td> <td>Choueiri TK, Powles T, Peitola K, et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. <i>N Engl J Med</i>. 2024 Aug 22;391(8):710-721.<sup>27</sup></td> </tr> <tr> <td>藥名<sup>28</sup></td> <td>Lenvatinib 10-20 mg po qd<sup>28</sup></td> </tr> <tr> <td>Ref.<sup>28</sup></td> <td>Zachary Klaassen, MD, MSc – Urologic Oncologist, Assistant Professor of Urology, Georgia Cancer Center, Augusta University/Medical College of Georgia, @zklklassen_md on Twitter during the 2021 European Society for Medical Oncology (ESMO) Annual Congress 2021, Thursday, Sep 16, 2021 – Tuesday, Sep 21, 2021.<sup>28</sup></td> </tr> </table>	藥名(學名) <sup>23</sup>	Sunitinib 50 mg po 4/2 or 2/1 week (on/off) <sup>23</sup>	Ref. <sup>23</sup>	Robert J. Motzer, M.D., Thomas E. Hutson, D.O., Stéphane Oudard, M.D., Published January 11, 2007. <i>N Engl J Med</i> 2007;356:115-124. DOI: 10.1056/NEJMoa065044. VOL. 356 NO. 2 <sup>23</sup>	藥名 <sup>24</sup>	Axitinib 5mg po bid <sup>24</sup>	Ref. <sup>24</sup>	<i>The Lancet</i> . Volume 378, Issue 9807p1931-1939December 03, 2011. AXIS trial <sup>24</sup>	藥名 <sup>25</sup>	Everolimus 10mg po qd <sup>25</sup>	Ref. <sup>25</sup>	<i>Ann Oncol</i> . 2016 Mar;27(3):441-8. doi: 10.1093/annonc/mdv612. Epub 2015 Dec 17. <sup>25</sup>	藥名 <sup>26</sup>	Tivozanib 1.34 mg po day1-21 <sup>26</sup>	Ref. <sup>26</sup>	Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TivNivo-2 Study <sup>26</sup>	藥名 <sup>27</sup>	Belzutifan 120 mg po qd <sup>27</sup>	Ref. <sup>27</sup>	Choueiri TK, Powles T, Peitola K, et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. <i>N Engl J Med</i> . 2024 Aug 22;391(8):710-721. <sup>27</sup>	藥名 <sup>28</sup>	Lenvatinib 10-20 mg po qd <sup>28</sup>	Ref. <sup>28</sup>	Zachary Klaassen, MD, MSc – Urologic Oncologist, Assistant Professor of Urology, Georgia Cancer Center, Augusta University/Medical College of Georgia, @zklklassen_md on Twitter during the 2021 European Society for Medical Oncology (ESMO) Annual Congress 2021, Thursday, Sep 16, 2021 – Tuesday, Sep 21, 2021. <sup>28</sup>
藥名(學名) <sup>23</sup>	Sunitinib 50 mg po 4/2 or 2/1 week (on/off) <sup>23</sup>																									
Ref. <sup>23</sup>	Robert J. Motzer, M.D., Thomas E. Hutson, D.O., Stéphane Oudard, M.D., Published January 11, 2007. <i>N Engl J Med</i> 2007;356:115-124. DOI: 10.1056/NEJMoa065044. VOL. 356 NO. 2 <sup>23</sup>																									
藥名 <sup>24</sup>	Axitinib 5mg po bid <sup>24</sup>																									
Ref. <sup>24</sup>	<i>The Lancet</i> . Volume 378, Issue 9807p1931-1939December 03, 2011. AXIS trial <sup>24</sup>																									
藥名 <sup>25</sup>	Everolimus 10mg po qd <sup>25</sup>																									
Ref. <sup>25</sup>	<i>Ann Oncol</i> . 2016 Mar;27(3):441-8. doi: 10.1093/annonc/mdv612. Epub 2015 Dec 17. <sup>25</sup>																									
藥名 <sup>26</sup>	Tivozanib 1.34 mg po day1-21 <sup>26</sup>																									
Ref. <sup>26</sup>	Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TivNivo-2 Study <sup>26</sup>																									
藥名 <sup>27</sup>	Belzutifan 120 mg po qd <sup>27</sup>																									
Ref. <sup>27</sup>	Choueiri TK, Powles T, Peitola K, et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. <i>N Engl J Med</i> . 2024 Aug 22;391(8):710-721. <sup>27</sup>																									
藥名 <sup>28</sup>	Lenvatinib 10-20 mg po qd <sup>28</sup>																									
Ref. <sup>28</sup>	Zachary Klaassen, MD, MSc – Urologic Oncologist, Assistant Professor of Urology, Georgia Cancer Center, Augusta University/Medical College of Georgia, @zklklassen_md on Twitter during the 2021 European Society for Medical Oncology (ESMO) Annual Congress 2021, Thursday, Sep 16, 2021 – Tuesday, Sep 21, 2021. <sup>28</sup>																									
第 49-50 頁	無	<p>新增</p> <p>註：任何期別無法遵循指引建議治療的病人，逐案經團隊討論決定治療方式及訂定完治定義。</p>																								

# 目 錄

一、前言	P.1
二、膀胱癌	P.2
2-1 症狀、診斷和檢查	P.2
2-2 組織病理分類與分化	P.2
2-3 分期	P.3
2-4 治療指引	P.5
2-5 外科治療處置	P.23
三、腎盂癌及輸尿管癌	P.24
3-1 症狀、診斷和檢查	P.24
3-2 組織病理分類與分化	P.24
3-3 分期	P.25
3-4 治療指引	P.26
3-5 外科治療處置	P.29
四、腎臟癌	P.29
4-1 症狀、診斷和檢查	P.29
4-2 組織病理分類與分化	P.29
4-3 分期	P.30
4-4 治療指引	P.31
4-5 外科治療處置	P.33



五、化學及放射線治療	P.33
5-1 泌尿上皮癌(含腎盂癌、輸尿管癌、膀胱癌)	P.33
5-2 腎臟癌	P.42
六、安寧緩和照護原則	P.46
七、參考文獻	P.47
八、泌尿道癌各期治療完治定義	P.48



## 一、前言

本共識手冊內所提之各種診治意見，為原則性之建議，希望能為癌症患者及其家屬提供一個正確的指引；但對臨床醫師之醫療行為無絕對之法律性約束力！由於醫藥科技持續在進步，每位患者的病情亦不盡相同；醫師應就病人之病情做個別的考量，病人和家屬亦應與醫師溝通討論，以決定最適當之診治方式。

根據2022年12月出版的國健署癌症登記年報，腎惡性腫瘤(C64)發生個案數占全部惡性腫瘤發生個案數的1.35%，當年因此死亡人數占全部惡性腫瘤死亡人數的1.14%。發生率的排名於男性為第15位、女性為第17位；死亡率的排行於男性為第14位、女性為第17位；腎盂及其他泌尿器官惡性腫瘤(C65-66,C68)發生個案數占全部惡性腫瘤發生個案數的1.42%，當年因此惡性腫瘤死亡人數占全部惡性腫瘤死亡人數的1.34%。發生率的排名於男性為第17位、女性為第14位；死亡率的排行於男性為第16位、女性為第13位；膀胱惡性腫瘤(C67)發生個案數占全部惡性腫瘤發生個案數的1.99%，當年因此惡性腫瘤死亡人數占全部惡性腫瘤死亡人數的2.12%。發生率的排名於男性為第11位、女性為第16位；死亡率的排行於男性為第11位、女性為第14位。

本院自2009年6月開始由泌尿外科、病理科、醫學影像部、放射腫瘤科與血液/腫瘤內科組成膀胱癌團隊，個案數逐年增加，自2023年4月癌委會提案通過除膀胱癌，新增腎癌、腎盂癌、輸尿管癌為泌尿道系統癌。本院泌尿道系統癌治療，藉由科際合作及定期開會討論，得到很好的治療成果。尤其是本院的病人中有一定的比例是腎移植後併發癌病的泌尿移行上皮細胞癌，他們的移行上皮細胞癌，常是多發性，散見於病人本身已衰竭的腎臟，或是輸尿管及膀胱上，我們認為若能在病人發生血尿或腰痛時作篩檢，將可提早發現癌症這個併發症。這也讓我們累積了相當豐富的處理經驗及成為中台灣腎移植病人照顧中心。

本院泌尿道系統癌診斷及治療指引的建立，除了依據已發表的實證醫學證據及專家意見外，並參考國家衛生研究院膀胱癌臨床指引、美國National Comprehensive Cancer Network (NCCN) 的 Practice Guide-lines in Bladder Cancer-V5 2024版、及中山醫學大學附設醫院泌尿道系統癌治療經驗進行編修。



## 二、膀胱癌

### 2-1 症狀、診斷和檢查

膀胱癌的一些常見症狀包括：

- (1)血尿（顏色呈淺褐色至深紅色）。
- (2)解尿疼痛。
- (3)頻尿或是常有尿意感但卻無小便。

當上述這些症狀產生時，並不確定是膀胱癌。也有可能是因為感染，良性腫瘤、膀胱癌結石或其它原因所造成，必須靠醫師來確定診斷，如此才能早期診斷，早期治療。

為了找出症狀的原因，醫生會詢問患者的病史並執行一些身體檢查。身體檢查包括直腸或陰道檢查，來幫助醫師檢查是否有腫瘤的存在。另外，尿液檢體會被送到實驗室檢驗來檢查是否有血液和癌細胞的存在。

使用膀胱鏡檢查直接檢查膀胱，檢查過程可能需要採局部或全身麻醉，可藉由膀胱鏡取出組織標本做切片檢查，這是唯一可以確定是否有癌細胞的方法。如果整個癌症在膀胱鏡下切片時被移除，膀胱癌便在單一的治療程序下被診斷及治療。膀胱癌的分期可能在診斷的同時就可以確定，或者它可能需要再做一些其它的檢查。這些檢查可能包括影像學檢查--電腦斷層掃描、磁振造影、超音波、靜脈腎盂攝影術、骨骼掃描或胸腔 X 光等。

### 2-2 組織病理分類與分化

膀胱癌的病理組織分化依2004 WHO grading分為：

Urothelial papilloma

Papillary urothelial neoplasm of low malignant potential (PUNLMP)

Low-grade papillary urothelial carcinoma

High-grade papillary urothelial carcinoma



## 2-3 分期

American Joint Committee on Cancer (AJCC)TNM Staging System for **Bladder Cancer** 8th ed., 2017)

T		Primary Tumor
TX		Primary tumor cannot be assessed
T0		No evidence of primary tumor
Ta		Non-invasive papillary carcinoma
Tis		Urothelial carcinoma in situ:“flat tumor”
T1		Tumor invades lamina propria (subepithelial connective tissue)
T2		Tumor invades muscularis propria
	pT2a	Tumor invades superficial muscularis propria (inner half)
	pT2b	Tumor invades deep muscularis propria (outer half)
T3		Tumor invades perivesical tissue
	pT3a	microscopically
	pT3b	macroscopically (extravesical mass)
T4		Extravesical tumor directly invades any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall
	T4a	Extravesical tumor invades prostatic stroma, seminal vesicles, uterus, vagina
	T4b	Extravesical tumor invades pelvic wall, abdominal wall

N	Regional Lymph Nodes
NX	Lymph nodes cannot be assessed
N0	No lymph node metastasis
N1	Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node)
N2	Multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis)
N3	Lymph node metastasis to the common iliac lymph nodes

M	Distant Metastasis
M0	No distant metastasis
M1	Distant metastasis
M1a	Distant metastasis limited to lymph nodes beyond the common iliacs
M1b	Non-lymph node distant metastasis



When T is...	And N is...	And M is...	Then the stage group is...
Ta	N0	M0	0a
Tis	N0	M0	0is
T1	N0	M0	I
T2a	N0	M0	II
T2b	N0	M0	II
T3a, T3b, T4a	N0	M0	IIIA
T1 - T4a	N1	M0	IIIA
T1 - T4a	N2, N3	M0	IIIB
T4b	Any N	M0	IVA
Any T	Any N	M1a	IVA
Any T	Any N	M1b	IVB



### 2-4 治療指引

#### INITIAL DIAGNOSIS

#### WORK-UP

#### CLINICAL STAGE

#### INITIAL THERAPY

■Cystoscopy  
 Urine cytology Then TURBt  
  
 Optional  
 ■Single-dose intravesical chemotherapy within 24hours of TURBT  
 Gemcitabine (preferred)  
 or  
 Mitomycin (preferred)


主要項目：  
 Abdominal/  
 Pelvic CTor MRI  
 選擇性項目：  
 ■Bone scan  
 ■CXR  
 ■PDL1

Non-muscle invasive bladder cancer (NMIBC)

Muscle invasive Bladder cancer (MIBC)

Ta  
 T1  
 Tis  
 詳見 P7

Stage II (cT2, N0) 詳見 P9  
 Stage IIIA (cT3, N0;cT4a, N0; cT1-T4a, N1) 詳見 P10  
 Stage IIIB (cT1-T4a, N2,3) 詳見 P11  
 Stage IVA (cT4b, Any N, M0; Any T, Any N, M1a) 詳見 P12  
 Metastatic (Stage IVB Any T, Any N, M1b) 詳見 P13




AUA Risk Stratification for Non-Muscle Invasive Bladder Cancer

Low Risk	Intermediate Risk	High Risk
<ul style="list-style-type: none"> <li>• Papillary urothelial neoplasm of low malignant potential</li> <li>• Low grade urothelial carcinoma               <ul style="list-style-type: none"> <li>➤ Ta and</li> <li>➤ ≤3 cm and</li> <li>➤ Solitary</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Low grade urothelial carcinoma               <ul style="list-style-type: none"> <li>➤ T1 or</li> <li>➤ &gt;3 cm or</li> <li>➤ Multifocal or</li> <li>➤ Recurrence within 1 year</li> </ul> </li> <li>• High grade urothelial carcinoma               <ul style="list-style-type: none"> <li>➤ Ta and</li> <li>➤ ≤3 cm and</li> <li>➤ Solitary</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• High grade urothelial carcinoma               <ul style="list-style-type: none"> <li>➤ CIS or</li> <li>➤ T1 or</li> <li>➤ &gt;3 cm or</li> <li>➤ Multifocal</li> </ul> </li> <li>• Very high risk features (any):               <ul style="list-style-type: none"> <li>➤ BCG unresponsivel</li> <li>➤ Variant histologies</li> <li>➤ Lymphovascular invasion</li> <li>➤ Prostatic urethral invasion</li> </ul> </li> </ul>





MANAGEMENT PER NMIBC RISK GROUP





### Management of Positive Urine Cytology








\*poor performance: ECOG ≥ 2 old age: ≥ 70 y/o  
 \*\*pT3-4, positive node, high grade (grade 2-3), positive margin



WORK-UP	INITIAL THERAPY	ADJUVANT THERAPY
---------	-----------------	------------------










# TREATMENT OF RECURRENCE OR PERSISTENT DISEASE





# Urothelial Carcinoma of the Prostate


WORKUP

PATHOLOGY

ADDITIONAL WORKUP

PRIMARY TREATMENT

PRIMARY TREATMENT






# Primary Carcinoma of the Urethra

WORKUP

DIAGNOSIS





# Primary Carcinoma of the Urethra


CLINICAL STAGING

ADDITIONAL WORKUP

PRIMARY TREATMENT

ADJUVANT TREATMENT

THERAPY FOR RECURRENCE






# Primary Carcinoma of the Urethra

CLINICAL STAGING

ADDITIONAL WORKUP

PRIMARY TREATMENT

THERAPY FOR RECURRENCE





**FOLLOW – UP**

AUA Risk Stratification for Non-muscle invasive Bladder Cancer		
Low Risk	Intermediate Risk	High Risk
<ul style="list-style-type: none"> <li>▶ Papillary urothelial neoplasm of low malignant potential</li> <li>▶ Low grade(LG)               <ul style="list-style-type: none"> <li>● Solitary and</li> <li>● Ta and</li> <li>● ≤3 cm</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Low grade urothelial carcinoma T1 or &gt;3 cm or Multifocal or Recurrence within 1 year</li> <li>• High grade urothelial carcinoma Ta and ≤3 cm and Solitary</li> </ul>	<ul style="list-style-type: none"> <li>• High grade urothelial carcinoma CIS or T1 or &gt;3 cm or Multifocal</li> <li>• Very high risk features (any): BCG unresponsive Variant histologies Lymphovascular invasion Prostatic urethral invasion</li> </ul>

Low-Risk, Non-muscle invasive Bladder Cancer							
test	year						
	1	2	3	4	5	5-10	>10
cystoscopy	3,12	annually				As clinically indicated	
Upper tract and abdominal/pelvic image	Baseline imaging	As clinically indicated					
Blood tests	N/A						
Urine tests	N/A						



Intermediate Risk, Non-muscle invasive Bladder Cancer							
test	year						
	1	2	3	4	5	5-10	>10
cystoscopy	3,6,12	Every 6 mo	annually			As clinically indicated	
Upper tract and abdominal/pelvic image	Baseline imaging	As clinically indicated					
Blood tests	N/A						
Urine tests	Urine cytology 3,6,12	Urine cytology every 6 mo	annually			As clinically indicated	

High Risk, Non-muscle invasive Bladder Cancer								
test	year							
	1	2	3	4	5	5-10	>10	
cystoscopy	Every 3 mo		Every 6 mo			annually	As clinically indicated	
Upper tract image	Baseline imaging, and at 12 mo	Every 1-2 y					As clinically indicated	
Abdominal/pelvic image	Baseline imaging	As clinically indicated						
Blood tests	N/A							
Urine tests	Urine cytology every 3mo Consider urinary urothelial tumor markers*optional		Urine cytology every 6mo			annually	As clinically indicated	



Post-cystectomy Non-muscle invasive Bladder Cancer								
test	year							
	1	2	3	4	5	5-10	>10	
cystoscopy	N/A							
image	CTU or MRU(image upper tracts + axial imaging of abd/pelvis at 3 and 12 mo)	CTU or MRU(image upper tracts + axial imaging of abd/pelvis) annually				Renal US annually	As clinically indicated	
Blood tests	<ul style="list-style-type: none"> <li>·Renal function testing(electrolytes and creatinine every 3-6 mo)</li> <li>·LFT every 3-6 mo</li> <li>·CBC,CMP every 3-6 mo if received chemotherapy</li> </ul>	<ul style="list-style-type: none"> <li>·Renal function testing(electrolytes and creatinine)annually</li> <li>·LFT annually</li> <li>·B12 annually*optional</li> </ul>				B12 annually*optional		
Urine tests	Urine cytology every 6-12 mo Consider urethral wash cytology every6-12 mo*optional		Urine cytology as clinically indicated urethral wash cytology as clinically indicated					

Post-cystectomy Muscle invasive Bladder Cancer								
test	year							
	1	2	3	4	5	5-10	>10	
cystoscopy	N/A							
image	<ul style="list-style-type: none"> <li>·CTU or MRU(image upper tracts + axial imaging of abd/pelvis) every 3 and 6 mo</li> <li>·Chest X-ray or CT chest every</li> </ul>	<ul style="list-style-type: none"> <li>·Abd/pelvis CT or MRI annually</li> <li>·Chest X-ray or CT chest annually or</li> <li>·PET/CT only if metastatic disease suspected</li> </ul>				Renal US annually	As clinically indicated	



	3 and 6 mo or ·PET/CT only if metastatic disease suspected			
Blood tests	·Renal function testing(electrolytes and creatinine) every 3-6 mo ·LFT every 3-6 mo ·CBC,CMP every 3-6 mo if received chemotherapy	·Renal function testing(electrolytes and creatinine)annually ·LFT annually ·B12 annually*optional		B12 annually*optional
Urine tests	·Urine cytology every 6-12 mo ·Consider urethral wash cytology every6-12 mo*optional		Urine cytology as clinically indicated urethral wash cytology as clinically indicated	

Post- Bladder Sparing(ie,partial cystectomy or chemoradiation)							
test	year						
	1	2	3	4	5	5-10	>10
cystoscopy	every 3 mo		every 6 mo		annually		As clinically indicated
image	·CTU or MRU(image upper tracts + axial imaging of abd/pelvis) every 3 -6 mo for MIBC ·Chest X-ray or CT chest every 3 - 6 mo for MIBC or ·PET/CT only if metastatic disease suspected		·Abd/pelvis CT or MRI annually ·Chest X-ray or CT chest annually or ·PET/CT only if metastatic disease suspected			As clinically indicated	
Blood tests	·Renal function testing(electrolytes and	·Renal function testing(electrolytes and creatinine)As clinically indicated ·LFT As clinically indicated					



	creatinine) every 3-6 mo ·LFT every 3-6 mo ·CBC,CMP every 3-6 mo if received chemotherapy	
Urine tests	·Urine cytology every 6-12 mo	Urine cytology as clinically indicated

Metastatic Disease: Surveillance							
test	year						
	1	2	3	4	5	5-10	>10
cystoscopy	• Every 3–6 mo as clinically indicated						
image	<ul style="list-style-type: none"> <li>• CTU or MRU (image upper tracts + axial imaging of abdomen/pelvis) every 3–6 mo if clinically indicated and with any clinical change or new symptoms</li> <li>• CT chest/abdomen/pelvic every 3–6 mo and with any clinical change or new symptoms</li> </ul> Or FDG PET/CT (category 2B)						
Blood tests	<ul style="list-style-type: none"> <li>• CBC, CMP every 1–3 mo</li> <li>• B12 annually for patients who had undergone a cystectomy</li> </ul>						
Urine tests	• Urine cytology 5 as clinically indicated						



## 2-5外科治療處置

# Principles of Surgical Management

### ***TURBt: (Ta/T1)***

- Adequate resection with muscle if papillary high-grade lesion
- Reresection if incomplete initial resection, no muscle in specimen or large lesion

### ***TURBt: Tis***

- Multiple random biopsies
- Biopsy adjacent to tumor
- Prostate urethral biopsies

### ***TURBt: invasive***

Repeat resection:

- Any T1, any grade
- If no muscle in biopsy
- Small fragment of T2 insufficient to attribute risk
- Repeat TURBt should be considered if first TURBt does not allow adequate staging or attribution of risk factor for treatment selection or when using bladder preserving treatment by chemotherapy and/or RT

### ***SEGMENTAL ( PARTIAL ) CYSTECTOMY***

- Solitary lesion in location amenable to partial resection with adequate margin, no Tis
- Pelvic lymphadenectomy may be performed in conjunction with the partial cystectomy

### ***RADICAL CYSTECTOMY***

- Radical cystectomy should include bilateral node dissection at a minimum including common, internal and external iliac nodes and obturator nodes



### 三、腎盂癌及輸尿管癌

#### 3-1 症狀、診斷和檢查

腎臟是兩個呈蠶豆狀的器官，位於人體中線的兩側，左右各一個，右腎受到肝臟的影響，位置較左腎低。腎臟主要功能為製造尿液、排泄廢物、維持水份、血液酸鹼值及電解質平衡、及內分泌正常功能。80-85%的腎臟腫瘤都是惡性，好發於 50-70 歲的中老年人，左腎及右腎發生的機會各半。腎臟惡性腫瘤包括尿路上皮癌、腎細胞癌、淋巴癌、轉移癌、惡性肉瘤等，其中的尿路上皮癌(urothelial carcinoma, UC)舊稱移行性細胞癌(transitional cell carcinoma, TCC)，是由泌尿系統內的尿路上皮細胞病變衍化而成的癌症，可能發生於腎臟的腎盂或腎盞，也可能發生於輸尿管、膀胱、尿道等部位，而稱為腎盂(尿路上皮)癌、輸尿管(尿路上皮)癌、膀胱(尿路上皮)癌、尿道(尿路上皮)癌等。腎臟的腎盂及輸尿管(尿路上皮)癌的發生原因及治療方式相近，因此常合併討論。

主要症狀是無痛性血尿(56-98% )。其次是腰痛(30%)，大部份為漸進性的悶痛；有些則發生急性腎絞痛，乃因血塊或腫瘤堵塞泌尿道造成腎水腫。其餘症狀包括解尿疼痛不順、體重減輕、疲倦、貧血、食慾不振、骨頭疼痛等。這些症狀出現愈多時，大部份為較後期疾病。還有 15% 的病人完全無症狀，是攝影檢查時意外發現的。

不同於膀胱癌的診斷可使用膀胱鏡來檢查、診斷及治療，上泌尿道系統(腎臟、腎盂、輸尿管)的診斷則必須透過影像學檢查來了解腫瘤的概況及侵犯程度，來決定後續的治療計畫。

#### 3-2 組織病理分類與分化

Urothelial papilloma

Papillary urothelial neoplasm of low malignant potential (PUNLMP)

Low-grade papillary urothelial carcinoma

High-grade papillary urothelial carcinoma



## 3-3 分期

American Joint Committee on Cancer (AJCC)TNM Staging System for Renal Pelvis and Ureter Cancer (8th ed., 2017)

T	Primary Tumor
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Ta	Papillary noninvasive carcinoma
Tis	Carcinoma in situ
T1	Tumor invades subepithelial connective tissue
T2	Tumor invades the muscularis
T3	For renal pelvis only: Tumor invades beyond muscularis into peripelvic fat or the renal parenchyma. For ureter only: Tumor invades beyond muscularis into periureteric fat.
T4	Tumor invades adjacent organs, or through the kidney into the perinephric fat.

N	Regional Lymph Nodes
NX	Lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis $\leq 2$ cm in greatest dimension, in a single lymph node
N2	Metastasis $> 2$ cm in a single lymph node; or multiple lymph nodes
N3	Lymph node metastasis to the common iliac lymph nodes

M	Distant Metastasis
M0	No distant metastasis
M1	Distant metastasis


Stage	T	N	M
Stage 0a	Ta	N0	M0
Stage 0is	Tis	N0	M0
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T3	N0	M0
Stage IV	T4	NX, N0	M0
	Any T	N1	M0
	Any T	N2	M0
	Any T	Any N	M1



### 3-4 治療指引

## 腎盂癌

<b>WORK UP</b>	<b>PRIMARY TREATMENT</b>
----------------	--------------------------






# 輸尿管癌


## WORK UP      PRIMARY TREATMENT

**Urothelial carcinoma of the ureter**  
 必要項目：  
 ■Abdominal/Pelvic CT scan or MRI  
 ■CXR  
 次要項目：  
 ■Chest CT  
 ■Bone scan  
 ■PDL1





PATHOLOGIC STAGING	ADJUVANT TREATMENT	FOLLOW UP
--------------------	--------------------	-----------





### 3-5外科治療處置

標準的手術方法是腎臟輸尿管及膀胱袖口切除術(Nephroureterectomy with cuff of bladder)，視患者情形加做區域淋巴結做清除術(±regional lymphadenectomy)。

針對不適合手術的患者(例如：腎功能不好、體能狀況差、年紀大、共病多等)及不願意手術的患者，可考慮腎保留手術，例如：內視鏡腫瘤消融術。

## 四、腎臟癌

### 4-1 症狀、診斷和檢查

早期腎臟癌都沒有任何症狀，隨著腫瘤慢慢變大，病人開始會出現血尿(59%)、腰痛(41%)及腹部腫塊(45%)等症狀。等到腫瘤更進一步擴散，病人會合併有疲倦、食慾不佳、體重減輕、貧血、發燒……等症狀。若轉移到其它器官，如肝臟、肺臟、骨骼、腦部……，則又會引發各個不同器官的功能失調，但這已經是腎臟癌的末期表現了。

腎臟癌多半在無意中被發現，病人因為上述的症狀就醫時才發現的腎臟癌，大多數已是中後期。近年來由於健康檢查逐漸普及，意外發現較小的腎臟腫瘤，所以，定期的健康檢查有助於早期發現初期的腎臟癌。

診斷腎臟癌最常用的是超音波檢查和電腦斷層掃描檢查，電腦斷層掃描不僅可以確定腎臟腫瘤的大小、也可以看到腫瘤擴散的情形，是腎臟癌分期的重要工具之一。除了少數不典型的例子，絕大多數的病人是不需要做腫瘤的切片檢查，減少擴散的風險。一般的血液檢查對腎臟癌的診斷較沒有幫助。小便檢查有可能出現血尿，但不一定。胸部 X 光是例行的檢查，看有沒有肺部的轉移。若有懷疑，骨骼的核子掃描可幫助判斷是否有骨骼轉移

### 4-2 組織病理分類與分化

腎細胞癌(Renal cell carcinoma)是最常見的腎臟癌，占總數 70~80%，腎細胞癌是由腎元的近端小管所長出，在病理上可分為亮細胞(Clear cell)、顆粒細胞、柱狀乳頭型及類肉瘤型。



## 4-3 分期

## American Joint Committee on Cancer (AJCC)TNM Staging System for Kidney Cancer (8th ed., 2017)

T		Primary Tumor
TX		Primary tumor cannot be assessed
T0		No evidence of primary tumor
T1		Tumor $\leq 7$ cm in greatest dimension, limited to the kidney
	T1a	Tumor $\leq 4$ cm in greatest dimension, limited to the kidney
	T1b	Tumor $>4$ cm but $\leq 7$ cm in greatest dimension, limited to the kidney
T2		Tumor $>7$ cm in greatest dimension, limited to the kidney
	T2a	Tumor $>7$ cm but $\leq 10$ cm in greatest dimension, limited to the kidney
	T2b	Tumor $>10$ cm, limited to the kidney
T3		Tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia
	T3a	Tumor extends into the renal vein or its segmental branches, or invades the pelvicalyceal system, or invades perirenal and/or renal sinus fat but not beyond Gerota's fascia
	T3b	Tumor extends into the vena cava below the diaphragm
	T3c	Tumor extends into the vena cava above the diaphragm or invades the wall of the vena cava
T4		Tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland)

N	Regional Lymph Nodes
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in regional lymph node(s)

M	Distant Metastasis
M0	No distant metastasis
M1	Distant metastasis


Stage	T	N	M
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T1-T2	N1	M0
	T3	NX,N0-N1	M0
Stage IV	T4	Any N	M0
	Any T	Any N	M1

PRIMARY TREATMENT

ADJUVANT TREATMENT



### 4-4治療指引






RELAPSE OR STAGE IV

TREATMENT

DISEASE PROGRESSION





## 4-5 外科治療處置

標準的手術方法是將腎臟、腎上腺、及腎周圍筋膜、腎周圍脂肪、還有局部的淋巴結全部切除，稱為根治性腎臟切除術(radical nephrectomy)。

若腫瘤小於4公分且位於腎臟週邊區，可考慮部份腎臟切除術(partial nephrectomy)。

其他不適合手術的患者可選擇冷凍療法(Cryosurgery)、內視鏡消融術等。

## 五、化學及放射線治療

### 5-1 泌尿上皮癌(含腎盂癌、輸尿管癌、膀胱癌)

#### Principles of SYSTEMIC THERAPY

##### *Intravesical chemotherapy for Tis ,Ta 及 T1 cancer*

Gemcitabine 每次灌洗 2000mg，連續三周每周兩次

Mitomycin (Miomycin-C) 30mg qw x6 and /or qm x3

Phamarubicin 30mg qw x6 and/or qm x3

BCG 120mg qw x6 and/or qm x3

Neoadjuvant chemotherapy [preferred for bladder]	Perioperative/Sandwich Therapy
<p><u>Preferred regimen</u></p> <ul style="list-style-type: none"> <li>• DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin) with growth factor support for 3-6 cycles</li> </ul> <p><u>Other recommended regimens</u></p> <ul style="list-style-type: none"> <li>• Gemcitabine and cisplatin for 4 cycles</li> </ul>	<p><u>Preferred regimen</u></p> <ul style="list-style-type: none"> <li>• <u>Gemcitabine + cisplatin + durvalumab prior to cystectomy, then durvalumab after cystectomy<sup>5</sup> (for bladder cancer only) (category 1)</u></li> </ul>



<b>Adjuvant therapy</b>	
No previous platinum-based neoadjuvant therapy (pT3, pT4a, pN+)	Preferred regimen
Preferred regimen	Other recommended regimen
<ul style="list-style-type: none"> <li>•DDMVAC with growth factor support for 3–6 cycles<sup>1,2</sup></li> <li>Other recommended regimens</li> <li>•Gemcitabine and cisplatin for 4 cycles<sup>3,4</sup></li> <li>•Nivolumab<sup>6</sup></li> <li>•Pembrolizumab<sup>7</sup></li> </ul>	<ul style="list-style-type: none"> <li>•Nivolumab<sup>6</sup></li> <li>•Pembrolizumab</li> </ul>

<b>Radio-sensitizing Chemotherapy Regimens</b>
<u>Preferred regimens</u>
<ul style="list-style-type: none"> <li>• Cisplatin alone</li> <li>• Low-dose gemcitabine</li> <li>• 5-FU and mitomycin</li> </ul>
Other recommended regimen
<ul style="list-style-type: none"> <li>• Cisplatin and 5-FU</li> <li>• Cisplatin and paclitaxel</li> </ul>
Useful in certain circumstances (not generally used for curative-intent chemoradiotherapy for organ preservation)
<ul style="list-style-type: none"> <li>• Taxane (docetaxel or paclitaxel) (category 2B)</li> <li>• 5-FU (category 2B)</li> <li>• Capecitabine (category 3)</li> </ul>

***Neoadjuvant regimens***

**MVAC**

Methotrexate	30 mg/m <sup>2</sup> iv	d1, 15 and 22
Vinblastine	3 mg/m <sup>2</sup> iv	d2, 15 and 22
Doxorubicin	30 mg/m <sup>2</sup> iv	d2
Cisplatin	70 mg/m <sup>2</sup> iv	d1
or Carboplatin(if Cr<60)	AUC 4-6	d2
Q4w x 3 cycles		

Grossman HB et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Eng J Med 2003; 349:859



**Adjuvant regimens****CheckMate 274**

Nivolumab	240 mg	q2w
1 year		

Dean F. Bajorin, M.D., J. Alfred Witjes, M.D., Matthew D. Galsky, M.D. Published June 2, 2021. N Engl J Med 2021;384:2102-2114. DOI: 10.1056/NEJMoa2034442.VOL. 384 NO. 222

**MVAC**

Methotrexate	30 mg/m <sup>2</sup> iv	d1, 15 and 22
Vinblastine	3 mg/m <sup>2</sup> iv	d2, 15 and 22
Doxorubicin	30 mg/m <sup>2</sup> iv	d2
Cisplatin	70 mg/m <sup>2</sup> iv	d1
Carboplatin	AUC 4-6	d1
Avelumab	10mg/Kg	q2w
Q4w x 6 cycles		
Useful under certain circumstances		

Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:2638-2646.

**EV 301 trial**

Enfortumab vedotin-ejfv	1.25 mg/kg	d1, 8, 15
q4w		

Thomas Powles, M.D., Jonathan E. Rosenberg, M.D., Daniel P. Petrylak, M.D. Author Info & Affiliations, Published February 12, 2021. N Engl J Med. 2021;384:1125-1135. DOI: 10.1056/NEJMoa2035807.VOL. 384 NO. 12.

**Gemcitabine+Carboplatin**

Gemcitabine	800 - 1000 mg/m <sup>2</sup> iv	d1, 8 and 15
Carboplatin	AUC 4-6	d1
Q4w x 4 cycles		

Von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068

**Gemcitabine+ Cisplatin**

Gemcitabine	800 - 1000 mg/m <sup>2</sup> iv	d1, 8 and 15
Cisplatin	70 mg/m <sup>2</sup> iv d2	d1
Q4w x 4 cycles		

Von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068

***Chemotherapy for metastatic cancer*****Principles of systemic therapy**

<b>First-line chemotherapy for locally advanced or metastatic disease(Stage IV)</b>	
Cisplatin eligible	<p><u>Preferred regimens</u></p> <ul style="list-style-type: none"> <li>• Pembrolizumab and enfortumab vedotin-ejfv (category 1)</li> </ul> <p><u>Other recommended regimens</u></p> <ul style="list-style-type: none"> <li>• Gemcitabine and cisplatin (category 1) followed by avelumab maintenance therapy (category 1)</li> <li>• Nivolumab, gemcitabine, and cisplatin (category 1) followed by nivolumab maintenance therapy(category 1)</li> </ul> <p><u>Useful under certain circumstances</u></p> <ul style="list-style-type: none"> <li>• DDMVAC with growth factor support (category 1)followed by avelumab maintenance therapy (category 1)</li> </ul>
Cisplatin ineligible	<p><u>Preferred regimens</u></p> <ul style="list-style-type: none"> <li>• Gemcitabine and carboplatin followed by avelumab maintenance therapy</li> <li>• Pembrolizumab (for the treatment of patients with locally advanced or metastatic urothelial carcinoma whoare not eligible for any platinum-containing chemotherapy)</li> <li>• Pembrolizumab and enfortumab vedotin-ejfv</li> </ul> <p><u>Other recommended regimens</u></p> <ul style="list-style-type: none"> <li>• Gemcitabine</li> <li>• Gemcitabine and paclitaxel</li> <li>• Atezolizumab (only for patients whose tumors express PD-L1) (category 2B)</li> </ul> <p><u>Useful under certain circumstances</u></p> <ul style="list-style-type: none"> <li>• Ifosfamide, doxorubicin, and gemcitabine (for patients with good kidney function and good PS)</li> <li>• Atezolizumab (only for patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 expression) (category 3)</li> </ul>



<b>Second-Line Systemic Therapy for Locally Advanced or Metastatic Disease (Stage IV)</b>		
<b>Previous immunotherapy and enfortumab vedotin-ejfv (no previous chemotherapy)</b>		
<u>Preferred regimens</u> <ul style="list-style-type: none"> <li>• DDMVAC with growth factor support</li> <li>• Gemcitabine and cisplatin</li> <li>• Gemcitabine and carboplatin (category 2B)</li> <li>• Enfortumab vedotin-ejfv</li> <li>• Enfortumab vedotin-ejfv and pembrolizumab</li> <li>• Biomarker-directed therapy (see biomarker-directed therapy table)</li> </ul>	<u>Other recommended regimens</u> <ul style="list-style-type: none"> <li>• Paclitaxel or docetaxel</li> <li>• Gemcitabine</li> </ul>	<u>Useful in certain circumstances</u> <ul style="list-style-type: none"> <li>• Gemcitabine, cisplatin, and nivolumab (category 2B)</li> <li>• Ifosfamide, doxorubicin, and gemcitabine30(category 2B)</li> <li>• Gemcitabine and paclitaxel31 (category 2B)</li> </ul>
<b>Previous chemotherapy (no previous immunotherapy or enfortumab vedotin-ejfv)</b>		
<u>Preferred regimens</u> <ul style="list-style-type: none"> <li>• Pembrolizumab (category 1 post-platinum)</li> <li>• Enfortumab vedotin-ejfv and pembrolizumab</li> <li>• Enfortumab vedotin-ejfv</li> <li>• Nivolumab(category 2B)</li> <li>• Avelumab (category 2B)</li> <li>• Biomarker-directed therapy (see biomarker-directed therapy table)</li> </ul>	<u>Other recommended regimens</u> <ul style="list-style-type: none"> <li>• Paclitaxel or docetaxel</li> <li>• Gemcitabine</li> </ul>	<u>Useful in certain circumstances</u> <ul style="list-style-type: none"> <li>• DDMVAC with growth factor support2 (category 2B)</li> <li>• Ifosfamide, doxorubicin, and gemcitabine30 (category 2B)</li> <li>• Gemcitabine and paclitaxel31 (category 2B)</li> <li>• Gemcitabine and cisplatin4 (category 2B)</li> </ul>
<b>Previous chemotherapy and immunotherapy (no previous enfortumab vedotin-ejfv)</b>		
<u>Preferred regimens</u> <ul style="list-style-type: none"> <li>• Enfortumab vedotin-ejfv(category 1)</li> <li>• Biomarker-directed therapy (see biomarker-directed therapy table)</li> </ul>	<u>Other recommended regimens</u> <ul style="list-style-type: none"> <li>• Enfortumab vedotin-ejfv and pembrolizumab</li> <li>• Paclitaxel or docetaxel</li> <li>• Gemcitabine</li> <li>• Gemcitabine and cisplatin4</li> <li>• DDMVAC with growth factor support2</li> <li>• Ifosfamide, doxorubicin, and gemcitabine (category 2B)</li> </ul>	<u>Useful in certain circumstances</u> <ul style="list-style-type: none"> <li>• Sacituzumab govitecan-hziy</li> </ul>



• Gemcitabine and paclitaxel (category 2B)		
<b>Subsequent-Line Systemic Therapy for Locally Advanced or Metastatic Disease (Stage IV)d,e</b>		
<b>Previous chemotherapy, immunotherapy, and enfortumab vedotin-ejfv</b>		
<u>Preferred regimen</u> • Biomarker-directed therapy Biomarker-directed therapy (see biomarker-directed therapy table)	<u>Other recommended regimens</u> • Gemcitabine • Paclitaxel or docetaxel • Ifosfamide, doxorubicin, and gemcitabine(category 2B) • Gemcitabine and paclitaxel31 (category 2B)	<u>Useful in certain circumstances</u> • Sacituzumab govitecan-hziy

***Unresectable/metastatic regimens*****MVAC**

Methotrexate	30 mg/m <sup>2</sup> iv	d1, 15 and 22
Vinblastine	3 mg/m <sup>2</sup> iv	d2, 15 and 22
Doxorubicin	30 mg/m <sup>2</sup> iv	d2
Cisplatin	70 mg/m <sup>2</sup> iv	d1
Carboplatin	AUC 4	d2
Q4w x 3 cycles		

Grossman HB et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Eng J Med 2003; 349:859

**Gemcitabine+ Cisplatin+ Nivolumab**

Gemcitabine	800 - 1000 mg/m <sup>2</sup> iv	d1, 8 and 15
Cisplatin	70 mg/m <sup>2</sup> iv	d1
Nivolumab	120-240mg	d1
Q4w x 3 cycles		

Von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068

**EV 302 trial**

Enfortumab Vendotin	1.25 mg/Kg	d1, 8
Pembrolizumab	200 mg	d1
Q3w x 4 cycles		
35 cycles for Pembrolizumab		

Thomas Powles, M.D., Gopa Iyer, M.D., Published March 6, 2024. N Engl J Med 2024;390:875-888. DOI: 10.1056/NEJMoa2312117. VOL. 390 NO. 10

**JAVELINE 100 trial**

Avelumab	10mg/Kg	q2w
Gemcitabine	1000-1250 mg/m <sup>2</sup> iv	d1, 8 and 15
Cisplatin	70 mg/m <sup>2</sup> iv	d1
Avelumab as 1st line maintenance		

Thomas Powles, M.D., Se Hoon Park, M.D., Ph.D., Petros Grivas, M.D., Ph.D. Author Info & Affiliations, Published September 18, 2020. N Engl J Med 2020;383:1218-1230. DOI: 10.1056/NEJMoa2002788. VOL. 383 NO. 13

**JAVELINE 100 trial**

Avelumab	10mg/Kg	q2w
Gemcitabine	1000-1250 mg/m <sup>2</sup> iv	d1, 8
Cisplatin	70 mg/m <sup>2</sup> iv	d1
Avelumab as 1st line maintenance		

Thomas Powles, M.D., Se Hoon Park, M.D., Ph.D., Petros Grivas, M.D., Ph.D. Author Info & Affiliations, Published September 18, 2020. N Engl J Med 2020;383:1218-1230. DOI: 10.1056/NEJMoa2002788. VOL. 383 NO. 13

**KeyNote 045 trial**

Pembrolizumab	200 mg	q3w
2 years		

Joaquim Bellmunt, M.D., Lawrence Fong, M.D., Nicholas J. Vogelzang, M.D., Published March 16, 2017, N Engl J Med 2017;376:1015-1026. DOI: 10.1056/NEJMoa1613683. VOL. 376 NO. 11

**TKI**

<b>藥名(學名)</b>	Erdafitinib 8 mg po daily initially; increase to 9 mg po daily
<b>Ref.</b>	<i>Yohann Loriot, M.D., Ph.D., Nobuaki Matsubara, M.D., Se Hoon Park, M.D., Ph.D., Robert A. Huddart, M.B., B.S., Ph.D., Earle F. Burgess, M.D., Banek, M.D., Published October 20, 2023 N Engl J Med 2023;389:1961-1971.DOI: 10.1056/NEJMoa2308849.VOL. 389 NO. 21</i>

**Principles of radiation (Bladder Cancer)**

Indication	Target Volume	建議劑量與分割 Dose & Fractionation	備註 Comments
Conventional fractionation	Whole bladder ± pelvic nodes	1.8–2.0 Gy / fraction	每日照射
Hypofractionation (definitive)	Whole bladder	55 Gy / 20 fractions	Non-inferior to 64 Gy/32 fx
Definitive RT (initial)	Whole bladder	39.6–50.4 Gy	需後續 boost
Definitive RT (boost)	Whole or partial bladder	Total 60–66 Gy	依腫瘤位置調整
Positive margin / ENE	Tumor bed / involved nodes	54–60 Gy	高風險區域
Adjuvant RT	Pelvic nodes (post-RC)	45–50.4 Gy	pT3–4, pN0–2
Adjuvant RT (boost)	Positive margin / ENE	Boost to 54–60 Gy	術後高風險
Palliative RT	Symptomatic lesion	30 Gy / 10 fx 或 21 Gy / 3 fx	止血、止痛



## 5-2 腎臟癌

## PRINCIPLES OF SYSTEMIC THERAPY FOR RELAPSE OR STAGE IV DISEASE

FIRST-LINE THERAPY FOR CLEAR CELL HISTOLOGY			
Risk	Preferred Regimens	Other Recommended Regimens	Useful in Certain Circumstances
Favorable	<ul style="list-style-type: none"> <li>• Axitinib + pembrolizumab (category 1)</li> <li>• Cabozantinib + nivolumab (category 1)</li> <li>• Lenvatinib + pembrolizumab (category 1)</li> <li>• Ipilimumab + nivolumab</li> </ul>	<ul style="list-style-type: none"> <li>• Axitinib + avelumab</li> <li>• Cabozantinib (category 2B)</li> <li>• Pazopanib</li> <li>• Sunitinib</li> </ul>	<ul style="list-style-type: none"> <li>• Active surveillance</li> <li>• Axitinib (category 2B)</li> </ul>
Poor/intermediate	<ul style="list-style-type: none"> <li>• Axitinib + pembrolizumab(category 1)</li> <li>• Cabozantinib + nivolumab (category 1)</li> <li>• Ipilimumab + nivolumab(category 1)</li> <li>• Lenvatinib + pembrolizumab(category 1)</li> <li>• Cabozantinib</li> </ul>	<ul style="list-style-type: none"> <li>• Axitinib + aveluma</li> <li>• Pazopanib</li> <li>• Sunitinib</li> </ul>	<ul style="list-style-type: none"> <li>• Axitinib (category 2B)</li> <li>•</li> </ul>

SUBSEQUENT THERAPY FOR CLEAR CELL HISTOLOGY (IN ALPHABETICAL ORDER BY CATEGORY)				
Immuno-oncology (IO)Therapy History Status	Preferred Regimens	Other Recommended Regimens	Useful in Certain Circumstances	
IO Therapy Naïve	<ul style="list-style-type: none"> <li>• None</li> </ul>	<ul style="list-style-type: none"> <li>• Axitinib + pembrolizumab</li> <li>• Cabozantinib</li> <li>• Cabozantinib + nivolumab</li> <li>• Ipilimumab + nivolumab</li> <li>• Lenvatinib + everolimus</li> <li>• Lenvatinib + pembrolizumab</li> <li>• Nivolumab</li> </ul>	<ul style="list-style-type: none"> <li>• Axitinib</li> <li>• Everolimus</li> <li>• Pazopanib</li> <li>• Sunitinib</li> <li>• Tivozanib</li> <li>• Belzutifan (category 2B)</li> <li>• Bevacizumab (category 2B)</li> </ul>	<ul style="list-style-type: none"> <li>• Axitinib + avelumab (category 3)</li> <li>• Lenvatinib</li> </ul>
Prior IO Therapy	<ul style="list-style-type: none"> <li>• None</li> </ul>	<ul style="list-style-type: none"> <li>• Axitinib</li> <li>• Cabozantinib</li> <li>• Lenvatinib + everolimus</li> <li>• Belzutifan</li> </ul>	<ul style="list-style-type: none"> <li>• Axitinib + pembrolizumab</li> <li>• Cabozantinib + nivolumab</li> <li>• Everolimus</li> <li>• Ipilimumab + nivolumab</li> <li>• Lenvatinib + pembrolizumab</li> <li>• Pazopanib</li> <li>• Sunitinib</li> </ul>	<ul style="list-style-type: none"> <li>• Bevacizumab(category 2B)</li> <li>• Axitinib + avelumab (category 3)</li> </ul>
SYSTEMIC THERAPY FOR NON-CLEAR CELL HISTOLOGY				



Preferred Regimens	Other Recommended Regimens	Useful in Certain Circumstances
<ul style="list-style-type: none"> <li>• Clinical trial</li> <li>• Cabozantinib</li> <li>• Nivolumab + cabozantinib</li> <li>• Lenvatinib + pembrolizumab</li> </ul>	<ul style="list-style-type: none"> <li>• Lenvatinib + everolimus</li> <li>• Nivolumab</li> <li>• Pembrolizumab</li> <li>• Sunitinib</li> <li>• Bevacizumab + erlotinib for selected patients with advanced papillary RCC including hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated RCC</li> </ul>	<ul style="list-style-type: none"> <li>• Axitinib</li> <li>• Bevacizumab + everolimus</li> <li>• Everolimus</li> <li>• Nivolumab + ipilimumab (category 2B)</li> </ul>

## unresectable/metastatic regimens

### CheckMate 9ER

Cabozantinib	40mg	qd
Nivolumab	240mg	q2w
Q4w x 6 cycles		

Choueiri TK, et al. N Engl J Med. 2021;384(9):829-841.

### CLEAR trial

Lenvatinib	20mg	qd
pembrolizumab	200 mg	q3w
Q4w x 6 cycles		

J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16.

### CheckMate 214 trial

Ipilimumab	1 mg/Kg	q3w
Nivolumab	3 mg/Kg	q3w
4 cycles then NIVO 3mg/Kg q2w		

Robert J. Motzer, M.D., Nizar M. Tannir, Elizabeth R. Plimack, M.D., Published March 21, 2018. N Engl J Med 2018;378:1277-1290  
DOI: 10.1056/NEJMoa1712126. VOL. 378 NO. 14

**KeyNote 426**

Pembrolizumab	200 mg	q3w
Axitinib	5mg	bid
35 cycles for Pembrolizumab		

Brian I. Rini, M.D., Elizabeth R. Plimack, M.D., Frédéric Pouliot, M.D., Ph.D., Published February 16, 2019. N Engl J Med 2019;380:1116-1127.DOI: 10.1056/NEJMoa1816714. VOL. 380 NO. 12

**KeyNote 045 trial**

Pembrolizumab	200 mg	q3w
2 years		

**TKI**

藥名(學名)	Cabozantinib 40-60 mg po qd
Ref.	<i>ToniK. Choueiri, M.D., Bernard Escudier, M.D., Thomas Powles, M.D., Hans Hammers, M.D., Published November 5, 2015, N Engl J Med 2015;373:1814-1823</i>

藥名(學名)	Pazopanib 800mg po qd
Ref.	<i>Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8</i>

藥名(學名)	Sunitinib 50 mg, po 4/2 or 2/1 week (on/off)
Ref.	<i>Robert J. Motzer, M.D., Thomas E. Hutson, D.O., Stéphane Oudard, M.D., Published January 11, 2007. N Engl J Med 2007;356:115-124. DOI: 10.1056/NEJMoa065044. VOL. 356 NO. 2</i>

藥名	Axitinib 5mg po bid
Ref.	<i>The Lancet. Volume 378, Issue 9807p1931-1939December 03, 2011. AXIS trial</i>



<b>藥名</b>	Everolimus 10mg po qd
<b>Ref.</b>	<i>Ann Oncol. 2016 Mar;27(3):441-8. doi: 10.1093/annonc/mdv612. Epub 2015 Dec 17.</i>
<b>藥名</b>	Tivozanib 1.34 mg po day1~21
<b>Ref.</b>	<i>Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study</i>
<b>藥名</b>	Belzutifan 120 mg po qd
<b>Ref.</b>	<i>Choueiri TK, Powles T, Peltola K, et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22;391(8):710-721.</i>
<b>藥名</b>	Lenvatinib 10~20 mg po qd
<b>Ref.</b>	<i>Zachary Klaassen, MD, MSc – Urologic Oncologist, Assistant Professor of Urology, Georgia Cancer Center, Augusta University/Medical College of Georgia, @zklaassen_md on Twitter during the 2021 European Society for Medical Oncology (ESMO) Annual Congress 2021, Thursday, Sep 16, 2021 – Tuesday, Sep 21, 2021.</i>



## Principle of radiotherapy (Renal cell carcinoma)

Indication	Target Volume	放射治療策略 RT Strategy	臨床備註 Comments
Localized RCC (可手術)	Primary kidney tumor	不建議常規 RT	手術仍為標準治療
Localized RCC (無法手術)	Primary kidney tumor	SBRT (局部根治性)	Medically inoperable / refusal of surgery
Stage I–III (非手術候選)	Primary tumor ± margin	High-dose hypofractionated RT / SBRT	高 BED 克服 radioresistance
Adjuvant setting	Renal bed / nodes	不建議 routine RT	未證實生存或局控改善
Local recurrence / residual	Recurrent lesion	SBRT / highly conformal RT	
Oligometastatic disease	Limited metastatic sites	Metastasis-directed RT (SBRT/SRS)	

## 六、安寧緩和照護原則

若預期疾病難以治癒時，病人存活期小於 6 個月便適合安寧療護(Pomeranz & Brustman, 2005；Waldrop & Rinfrette, 2009)。若藉由症狀、檢驗數據、及確切的腫瘤診斷，證實臨床上該惡性腫瘤已經廣泛侵犯、或進展快速；功能分數 (Palliative Performance Scale) 低於 70%；拒絕進一步腫瘤治癒性治療，或者在治療之下仍持續惡化者，即可轉介緩和醫療團隊 (彭等，2006)。



## 七、參考文獻

1. van der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, de Balincourt C. Significance of bladder biopsies in Ta,T1 bladder tumors: a report of the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 1999 Apr;35(4): 267-71.
2. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 2004 Jun;171(6 Pt 1):2186-90.
3. Miller DC, Taub DA, Dunn RL, Montie JE, Wei JT. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol 2003 Jan;169(1):105-9.
4. Stenzl A, Nagele U, Kuczyk M, Sievert K, Anastasiadis A, Seibold J, Corvin S. Cystectomy – Technical Considerations in Male and Female Patients. EAU Update Series 2005;3:138-46.
5. NCCN Clinical Practice Guidelines in Oncology Bladder Cancer. Version 1. 2013.
6. Grossman HB et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Eng J Med 2003; 349:859
7. Von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068
8. Tunio MA et al. Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation (SIUT). J Pak Med Assoc 2011; 61:6.
9. Han KS et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer 2008; 98:86.
10. Logothetis CJ et al. A prospective randomized trial comparing MVAC with CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8:1050.
11. NCCN Clinical Practice Guidelines in Oncology Bladder Cancer. Version 3. 2023.
12. NCCN Practice Guidelines in Oncology, 2025.
13. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer (AUA/ASCO/ASTRO/SUO) – 2017/Amended 2024.



14. Perez and Brady's : Principles and Practice of Radiation Oncology, 7th ed, 2018.  
15. Eric K. Hansen, Handbook of Evidence-Based Radiation Oncology.

## 八、泌尿系統癌各期治療完治定義

期別	治療方式	完治定義	備註
第0a期 第0期	TURBT ± 膀胱灌藥	完成TURBT ± 膀胱灌藥9次 (醫師視風險指標表建議後續追加膀胱灌藥)	
第I期	TURBT + IVI	完成TURBT + 膀胱灌藥9次	
第II期	1.Neo-adjuvant C/T + OP 2.OP 3.CCRT 4.TURBT or/and Intravesical chemotherapy 5.C/T+IO	1.完成膀胱切除術 or 2.完成放射線治療 or 3.完成TURBT + 膀胱灌藥9次 4. C/T+IO持續治療半年	
第IIIA期	1.Neo-adjuvant C/T + OP 2.OP 3.CCRT 4. C/T+IO	1.完成膀胱切除術 or 2.完成放射線治療 or 3. C/T+IO持續治療半年	
第IIIB期	1. Downstaging systemic therapy 2.CCRT	1.完成醫師規劃之療程並進入第一次影像追蹤 2.完成放射線治療	
第IV期	Systemic therapy	1.STAGE IV 接受全身性治療一次 or 2.STAGE IV 接受放射治療一個療程or 3.STAGE IV 接受安寧照護	



腎盂癌、輸尿管癌	期別	治療方式	完治定義	備註
	第0a期 第0期	1. OP 2. 內視鏡腫瘤消融術	1.完成腎臟輸尿管合併膀胱袖口切除術 2.完成內視鏡腫瘤消融術	
	第I期	1.OP 2. 內視鏡腫瘤消融術(視醫師評估)	1.完成腎臟輸尿管合併膀胱袖口切除術 2.完成內視鏡腫瘤消融術	
	第II期	1.Neo-adjuvant C/T+OP 2.OP	完成腎臟輸尿管合併膀胱袖口切除術	
	第III期	1.Neo-adjuvant C/T+OP 2.OP	完成腎臟輸尿管合併膀胱袖口切除術	
	第IV期	Systemic therapy	1.STAGE IV 接受全身性治療一次 or 2.STAGE IV 接受放射治療一個療程or 3.STAGE IV 接受安寧照護	

註：任何期別無法遵循指引建議治療的病人，逐案經團隊討論決定治療方式及訂定完治定義。



腎 臟 癌	期別	治療方式	完治定義	備註
	第I期	1.OP(含部分腎臟切除術、根治性腎臟切除術) 2.腫瘤消融術	1.完成醫師規劃之手術(含部分腎臟切除術、根治性腎臟切除術) 2. 完成腫瘤消融術	
	第II期	OP(含部分腎臟切除術、根治性腎臟切除術)	完成醫師規劃之手術(含部分腎臟切除術、根治性腎臟切除術)	
	第III期	OP(根治性腎臟切除術)	完成根治性腎臟切除術	
	第IV期	Systemic therapy	1.STAGE IV 接受全身性治療一次 or 2.STAGE IV 接受放射治療一個療程or 3.STAGE IV 接受安寧照護	

註：任何期別無法遵循指引建議治療的病人，逐案經團隊討論決定治療方式及訂定完治定義。